Journal articles on the topic 'Short stay accommodation'

Purpose This paper aims to provide a reliable statistical model for time-series prices of short-stay accommodation and overnight stays in a eurozone country. Design/methodology/approach Exploiting the unit root feature, the cointegrated vector autoregressive model solves the problem of misspecification. Subsequently, variables are modelled for a long-run equilibrium with included deterministic variables. Findings The empirical results confirmed that overnight stays for foreign tourists were positively associated with the prices of short-stay accommodation. Research limitations/implications The major limitation lies in the data vector and its time horizon; its extension could provide a more specific view. Practical implications Findings can assist practitioners and hotel executives by providing the information and rationale for adopting seasonal volatility pricing. Structural breaks in price time-series have practical implications for setting seasonal-pricing schemes. Tourists could benefit either from greater price stability or from differentiated seasonal prices, which are important in the promotion of the price attractiveness of the tourist destination. Originality/value The originality of the paper lies in the applied unit root econometrics for tourism price time-series modelling and the prediction of short-stay accommodation prices.

This study extends previous empirical efficiency research by focusing on a tourism sector which has limited evidence to date: the holiday and other short-stay accommodation industry (tourist apartments and hostels). The sample comprises 12,864 firm-level observations during the period 2005–2016. First, we calculate the efficiency index using a non-radial Data Envelopment Analysis (DEA). Second, we test the association between efficiency index and contextual factors using both Tobit and bootstrapped regression. Another major contribution is the use of a radial DEA model to confirm the results of the study. The current study offers new insights by focusing on an industry with scarce evidence, using radial and non-radial DEA approaches, and examining a wide variety of efficiency drivers. The efficiency results are examined by year, region and tourist destination type (including tourism dimensions such as rural, cultural and wine tourism). This is an important novelty of the study. The main findings reveal that the most efficient tourism destinations correspond to mixed or diversified destinations: those that combine some dimensions such as cultural, rural and wine tourism. The regressions models show that environmental, macroeconomic and business variables are drivers of tourism competitiveness. Taken together, the study goes a step further in the efficiency field.

During the COVID-19 pandemic, platform-mediated short-term rentals are believed to have performed better than traditional tourism accommodation due to tourist preferences and the possibility of evading some sanitary regulations. The paper investigates this difference in 31 European countries by combining conventional hotel statistics with novel data on short-stay accommodation (SSA) gathered by Eurostat from four major platforms mediating in home rentals. The first hypothesis that short-term rental accommodation lost fewer tourists during the pandemic than hotels is supported if domestic tourism is concerned. The second hypothesis that the loss of tourists in short-term rental accommodation was less dependent on the stringency of restrictions than in hotels is only confirmed for domestic tourism in small, primarily outbound tourism-generating countries. The study results shed light on the pandemic-induced travel substitution, discussion on the regulation of short-term rentals, and the utility of Eurostat SSA statistics as a new research data source.

Based on fine-grained data on short-term accommodations for the city of Barcelona, we review the uneven impact of the pandemic on the short-term market, differentiating the supply by type of accommodation: single room versus entire flat/house, and type of host: professionalized versus non-professionalized. Using a fixed effects approach at property level, we estimate an average decrease in prices of 11.3% in entire flat/house and 4.7% in single rooms. For professionalized supply, the effect arrived to 13.6% and 9.8%, respectively. Finally, a growth in minimum stay was experienced by all types, but with a stronger effect on professionalized accommodations. We suggest that the supply adaptation strategy to accommodate the decreasing demand, especially by professionalized hosts, was to attract a more stable demand coupled with lower prices and longer stays. In addition, the type of short-term supply that experienced the strongest drop in occupancy was the non-professionalized segment, loosing around 41% of their bookings between April 2020 and January 2021.

The spreading of short-term flat rentals has brought about changes in the accommodation market, often seen as a threat to traditional accommodation providers. This is particularly true in large cities which have a considerable accommodation capacity and also a large stock of flats. The aim is to indicate to what extent short-term rentals are influencing the tourist accommodation market in Warsaw. The idea behind the study is the assumption that the differences revealed between those using hotels or such flats will provide an answer to the question of the influence of the latter on Warsaw»s tourist market. Such information should be useful in the marketing activities of interested parties and in the policies of the city authorities. Analysis of the data from a survey carried out in 2021 using the CHAID decision tree indicates that the choice of accommodation type was mainly determined by situational variables. The only statistically significant demographic predictor relates to a greater interest in flats among those aged up to 34 years old. Planned expenditure per person per overnight stay proved to be a statistically significant predictor only for non-residents of Poland, with the cut-off amount set higher than the median interval for this segment. Flats were more often chosen by people travelling in a larger party or alone and those planning to stay longer than four nights, thus looking for a different offer than that of traditional city hotels.

AimsThe aims were to establish the mean length of stay (LOS) in the Wandsworth home treatment team (HTT), and to identify which variables were associated with LOS. We hypothesised that the variables that are routinely collected via the electronic record system were associated with the LOS.BackgroundPsychiatric HTT's have been set up in all NHS trusts in England. These 24-hour community health services exist to assess and manage patients during a crisis, who would otherwise be admitted to an acute psychiatric ward. HTT's also allow inpatients to be discharged sooner, as their treatment can continue in the community. Currently, research into predictors of LOS in HTT's is limited.Researchers have been exploring whether LOS in psychiatric inpatients can be predicted, but no consistent pattern has emerged. This suggests that LOS is mainly determined by the local service organisation, and the individual circumstances of the patients.MethodRoutinely collected data about all patients under the care of the Wandsworth HTT during the financial year 2018/2019 were used. Only the first admission per individual was considered. Admissions lasting less than 2 days, or more than 42 days were excluded. This is on the basis that those with a very short LOS had not consented to being treated at home, and those with a very long LOS were due to administrative errors. This resulted in a total of 664 admissions being included in the study. The available data for analysis included age, gender, diagnosis, HoNOS cluster, ethnicity, nationality, religion, marital status, referral source, employment status, accommodation status, and accommodation type. The data were analysed in SPSS version 25 using ANOVA, independent samples T-test, and Pearson's correlation.ResultThe mean LOS in the Wandsworth HTT was 14.28 days (standard deviation: 8.57). LOS was positively skewed, with a median LOS of 13 days, but 46.5% of admissions had a LOS longer than this. None of the variables (age, gender, diagnosis, HoNOS cluster, ethnicity, nationality, religion, marital status, referral source, employment status, accommodation status, and accommodation type) had a significant association with LOS, but there was a trend for referral source and accommodation type.ConclusionThe results from this study suggest that LOS cannot be consistently predicted in the Wandsworth HTT from the routinely collected variables, and that it is the specific circumstances of individual patients that determine their LOS.There was no external funding for this study.

Hotels play an important role in the tourism industry. Without a hotel, tourists would not be able to enjoy a comfortable vacation. This is because the hotel provides the services and other services you need for a comfortable stay. The hotel itself has the concept of a type of accommodation that is commercially operated, providing services such as accommodation, services and food and drink to the general public for a short stay. Medan has so many Star Hotel competitors that you need to develop an appropriate marketing strategy. Therefore, the right marketing strategy applicable in today's digital age is digital marketing, especially web-based applications. In this case, Hotel Santika Premiere Dyandra Medan also digitally marketed web-based applications and more. This is one of the mainstays for promoting and increasing room occupancy, which has been sluggish in recent years due to the Covid 19 pandemic. Web-based applications are called MySantika and MyValue. The benefits of the Internet and digital marketing are so great that you can benefit from the Internet in almost every area, including: B. Business sector through banking, insurance, travel, education, etc. Since the advent of the Internet, patterns of daily life have gradually changed.

Purpose The purpose of this paper is to map the service quality (SQ) of Airbnb, to provide additional insight for such top player of short-stay accommodation in the sharing economy context. Design/methodology/approach A mixed-method approach is used in two phases. In the qualitative phase, 112,138 online review comments of Airbnb guests were analyzed to generate the service attributes. In the quantitative phase, an online survey (n = 814) was conducted to calculate the performance and importance values of extracted attributes to plot them in an Importance-Performance Analysis (IPA) matrix. Findings A holistic image of the Airbnb extracted service attributes was presented through the IPA plot. Four types of SQ strategies were proposed, considering the actions priority. “Price reasonability” was the most important service attribute of Airbnb for guests, whereas “Check-in flexibility” was the best performed one. Practical implications The results shed light on the most relevant SQ attributes of Airbnb and proposed suitable strategies that can prioritize relevant stakeholders’ actions and decisions. The study significantly contributes to all decision makers involved in the short-stay accommodation sharing industry to further understand and develop SQ. Originality/value This research, using a comprehensive hybrid method, opens a lens to see more clearly the positioning of different attributes of Airbnb service from importance and performance viewpoints. As a contribution, the SQ of Airbnb was mapped by conducting an IPA for the first time in the literature.

In Korea, a house is meaningful as a basic place in people's lives. People put all their effort into purchasing housing that is equivalent to food, clothing, and shelter. For that reason, in our country, the price of real estate, especially housing, fluctuates depending on people's needs over time. Korea has achieved economic development through industrialization, but with the urban concentration phenomenon and the rapid increase in urban housing demand, housing supply and demand has become an important national task. Economic development brought about changes in residential culture, giving rise to various housing types, with the emergence of single-family homes, townhouses, and apartment-type apartment complexes. However, as it could not cope with the overwhelming demand, officetel, a combination of an office and a hotel, which was popular abroad, was introduced. This officetel was also resolved after the Oran controversy by separating officetels for office use and residential use. Similar to this issue, controversy arose over residential lodging facilities, which are residential-type lodging facilities. Accommodation facilities are for people to stay for a short period of time, and there are various types. Among them, there are condos where you can stay for a while and cook, but most of them are short-term lodging facilities. Then, the form of residential accommodation emerged as a way to solve the problem of surplus accommodation and insufficient housing in cities. Living accommodation facilities, which began in the early 21st century, were initially used for long-term stays like officetels, with cooking facilities installed, and used for residential purposes. Living accommodation facilities are lodging facilities, but as people live there for a long period of time, they are used like houses, and their number gradually increases. However, because there was no legal basis, it spread indiscriminately, and from the public's perspective, it came to be perceived as purchasing housing at a low price. It was only in 2012 that living accommodation facilities gained their basis in the Enforcement Decree of the Public Sanitation Management Act. However, living accommodations were only a type of accommodation and not housing. Since the legal basis for living accommodation facilities is that only one type of accommodation facility is specified in the Enforcement Decree of the Public Health Management Act, there are no regulations regarding this, so in reality, they are continuously built and sold. Meanwhile, in 2020, the legal status of residential lodging facilities, a type of lodging facility, became an issue, and issues began to be raised about the fact that these facilities were being used for residential purposes rather than lodging facilities. As a result, it became a problem as it was regulated through a two-year transition provision. Living accommodation facilities are equivalent to housing for citizens who live there. This will not be resolved by postponing administrative dispositions for two years and an additional year without fundamentally resolving the issue. Rather than allowing people who purchased it for residential purposes to change its use to officetel, which is impossible, we need to find appropriate standards that fit the reality, guarantee property rights, and protect trust. Therefore, we need to actively work to guarantee the basic rights of people who are users of living accommodation facilities. There must be action.

Natural disasters and subsequent man-made disasters have recently become regular. In these conditions, the primary task of the State is the organization of temporary accommodation points capable of providing the affected population with housing units in a short time. In addition, if it is impossible to equip permanent places of residence in a short time, there is a task to provide temporary accommodation facilities with the necessary infrastructure. The purpose of the research is to develop and substantiate technical proposals for the creation of temporary accommodation facilities for the population affected by a natural disaster. In order to achieve this goal, an analysis of the literature related to the existing methods of erecting temporary stay points and temporary accommodation towns for the affected population is carried out. Advanced solutions for the construction of prefabricated buildings are considered in order to determine the most optimal solution. The result of the work is a system of interrelated proposals aimed at solving the issue of providing the population with high-quality living space. The article substantiates decisions on the organization of planning, composition, as well as the order of installation and dismantling of temporary accommodation facilities. The results obtained can be used in the preparation of optimal solutions for the deployment of temporary towns for the population affected by the destructive actions of the elements.

Michel Foucault analysed the origins and social function served by institutions such as the prison and the clinic, explored the links between knowledge and power, and the body as a location or site of such social power. In this article, Foucault's analysis is applied to an Australian program for people who are homeless. After outlining a theoretical framework which emphases Foucault's theme of increasing surveillance being used for the purposes of greater regulation and control, this article analyses the changes that have occurred in the program. It is argued that initially the program was intended to assist non-government agencies to provide a range of services, including short-term crisis accommodation services, after which clients would move to independent housing. However, due to the lack of affordable and appropriate houses for clients to enter after their stay in agencies, clients have been forced to stay in funded agencies for longer than is otherwise necessary. Among other things, this program has adapted by providing more short-to-medium term accommodation and case management for clients which, in turn, has led to an extension of the time clients remain in agencies and greater intensity of service provision. It is argued that this has resulted in increased potential for surveillance, control and regulation.

Purpose The purpose of this paper is to critically evaluate an innovative collaboration between health, housing and social care by exploring the “short stay project” apartments from service users’ perspectives and considering the effectiveness of this service model as part of enabling provision locally. Design/methodology/approach The qualitative methodology for this evaluation was interpretative phenomenological analysis (Smith, 2011), critically exploring service users’ personal lived experience of the “short stay project”. Three service users (n=3) participated in semi-structured interviews. Findings This study has identified the “short stay project” can prevent admission into and facilitate discharge from care and health services by offering a temporary stay in self-contained, adapted accommodation. Service users found value in staying at the apartments for differing reasons. However, practitioners must address service users’ emotional and social needs as well as physical needs to reduce the risk of occupational deprivation. Research limitations/implications Sample size is not fully representative of the total population making transferability limited. Practical implications This research found there is demand for temporary housing provision for service users with health, housing and/or social care needs. Social implications Key drivers of demand for the service are social inequalities relating to homelessness, poverty and gender-based violence rather than the health-related issues that could have been expected. Further research into the development of effective integrated services which maximise service users’ wellbeing and occupational performance is recommended. Originality/value Service models which integrate health, housing and social care can be innovative and maintain service users’ independence and wellbeing in the community. Commissioners across health, housing and social care could utilise the Better Care Fund to deliver integrated services to meet rising demands.

Background: The practice of short stay thyroidectomy is relatively new in developing nations like Nigeria. The primary reason for this is a lack of resources. Furthermore, the prevailing poverty prevents many patients from accessing tertiary health care, as such, ad hoc medical outreaches are usually conducted to bridge the gap. Thyroidectomies have not been routinely performed in these outreach settings due to safety concerns. The study seeks to analyse whether short stay thyroidectomy can be safely practiced under medical outreach settings with limited resources.Methods: The study is a prospective review of all patients that had short stay thyroidectomy at four rural medical outreach settings in Nigeria. Entire study spanned January 2019 to November 2019. Each outreach lasted one week, and patients were followed up for the duration of the outreach. All patients presenting at the outreach locations and diagnosed with goiters who have had no prior neck surgeries, are euthyroid, have no locally advanced malignancies or intrathoracic goiters, have adequate social support, possess a telephone, and have accommodation within the local government area where the outreach is carried out were included in the study. Exclusion criteria included patients who did not satisfy any of the above listed inclusion criteria. Thyroidectomy was done through a standard cervicotomy. Descriptive statistics were applied.Results: A total of 81 patients with non-toxic goiters had thyroid surgery. There were 76 (94%) females and five (6%) males. Average age was 46 years. Sixty-nine (85.2%) patients had no complication, while 12 (14.8%) patients had complications. Seventy-seven (95.1%) patients were discharged within 24 hours of surgery, while four (9.4%) patients were discharged within 48 hours. There was no mortality.Conclusions: The short-stay thyroidectomy model is feasible and safe in our environment, even in the presence of limited resources, and provides an alternative to the traditional 72 hour postoperative hospital stay.

Purpose. The purpose of the article is to analyse the factors influencing the decision to choose couchsurfing as a manner of accommodation or even a way of organizing an entire stay. The specific objective of the study is to present the connection between the decision of accommodation choice and the lifestyle or to short-term, individual decisions related to fashion and the effect of imitation. Method. Individual in-depth interviews with the couchsurfers (users of Couchsurfing.org) were conducted. Findings. As a result, there was a correlation between the represented lifestyle and the way of organizing the visit with couchsurfing. The fashion and effect of imitation are not relevant and do not affect the choice of couchsurfing as a way of accommodation in the case of experienced people who used it more than once. Research and conclusions limitation. The exploratory character of the study and the small sample size are the limitation and do not allow to formulate general conclusions about couchsurfing. Practical implications. The analysis can determine further research on lifestyle as a factor influencing the choice of accommodation in the area of collaborative consumption. Originality. The individualization and personalization of tourism services can be observed. Couchsurfing is the manifestation of this phenomenon. It is based on mutual hospitality (free accommodation) and helps to buildrelationships between people. Previous studies did not verify the impact of fashion and the effect of imitation on the use of couchsurfing. Type of paper. This article presents the results of empirical research.

The paper presents the development of tourism in Maribor, with a focus on major changes in the tourist offer (especially tourist infrastructure and accommodation facilities) and tourist visit since 1991. Changes in tourist flows to South-East Europe, the great economic crises and the collapse of the major industrial companies in Maribor was followed by a large decrease in tourist visit and the need for transformation of the tourist offer in the city. In Maribor was built a range of new hotels and other accommodation facilities, which resulted in the fact that since 2000 increased diversity and quality of the tourist offer and, consequently, has gradually started to increase also the tourist visit. However, Maribor still shows all the characteristics of a tourist destination with the dominant urban tourism, which is characterized by short average length of stay of tourists and the high share of overnight stays in hotels.

Background. Few charitable overseas surgical missions produce cost-effectiveness analyses of their work. Methods. We compared the pre- and postoperative health status for 157 total hip arthroplasty (THA) patients operated on from 2007 to 2011 attended by an annual Canadian orthopedic mission to Ecuador to determine the quality-adjusted life years (QALYs) gained. The costs of each mission are known. The cost per surgery was divided by the average lifetime QALYs gained to estimate an incremental cost-effectiveness ratio (ICER) in Canadian dollars per QALY. Results. The average lifetime QALYs (95% CI) gained were 1.46 (1.4–1.5), 2.5 (2.4–2.6), and 2.9 (2.7–3.1) for unilateral, bilateral, and staged (two THAs in different years) operations, respectively. The ICERs were $4,442 for unilateral, $2,939 for bilateral, and $4392 for staged procedures. Seventy percent of the mission budget was spent on the transport and accommodation of volunteers. Conclusion. THA by a Canadian short-stay surgical team was highly cost-effective, according to criteria from the National Institute for Health and Care Excellence and the World Health Organization. We encourage other international missions to provide similar cost-effectiveness data to enable better comparison between mission types and between mission and nonmission care.

AbstractThis paper investigates the long-term cointegration between tourism prices and domestic inflation in Croatia and Slovenia. Those two countries share a common economic history and statistical crispness in the 20th century, the time when Econometrics was not a blossoming topic. The two countries split the common economic path in the 1990s and since then, econometricians have been tackling different development issues and researches. The purpose of the paper is to stress the importance of using a well-designed time-series methodology when dealing with multiple variables estimation and evaluation as well in designing adequate and efficient quantitative models, capable to provide valuable forecasts and predict external shocks. It is assumed that, at the basis of an efficient quantitative model, there is a need of unit root and errors normal distribution testing. To test the covariance of cointegration between tourism prices and domestic inflation, the vector autoregressive model (VAR) model is used on 260 valid monthly time-series observations (~ 22 years). The results have shown that prices of short-stay accommodation in Slovenia are cointegrated with domestic inflation, whereas in Croatia there is no stable cointegration vector on prices of accommodation services if / when analysed using the intervention dummy variables and a constant. Although the results indicate that the research hypothesis is generally confirmed, better and more robust results could be obtained including mean-shift dummy variables in a VAR model.

This paper presents a study on the architecture created for the needs of Maggie's, a charity organisation, whose main aim since 1995 has been the creation of facilities (centres) for the short-term stay of cancer patients and their families without accommodation options. The main purpose of Maggie's facilities is to provide patients and their loved ones with a sense of home security and peace during hospital therapies. This paper discusses several centres, located all over the world, as well as the features of shaping space common to the presented examples as determined. Their architectural layouts were analysed with a focus on patient needs and activity. Based on the designs of Maggie's Centres, we identified basic principles of design and interior arrangement that can be used in other medical buildings and those that require their patients to maintain a high degree of psychophysical comfort. This paper presents evidence of the importance of a homely atmosphere in healthcare settings.

In many places of the world, the interruption of touristic activities in the aftermath of a catastrophic earthquake is often neglected in the evaluation of seismic risks; however, these activities can account for a significant proportion of short-term and long-term economic impacts for these regions. In the last decade, several rapid visual screening techniques have been developed to define the typology of buildings and to estimate their seismic vulnerability and potential for damage. We adapted the existing screening procedures that have been developed for generic buildings to specific circumstances that are most common for tourist accommodations. The proposed approach considered six criteria related to structural and nonstructural elements of buildings, as well as local soil conditions. A score was assigned to each criterion as a function of the capacity of the elements to resist ground shaking. A vulnerability index in four levels of building vulnerability was developed combining the scores of the six criteria. The approach was tested in a pilot area of Montreal to a set of 70 typical buildings grouped in four categories based on their accommodation capacity. In Montreal, tourism is an important source of income for the city where 351,000 room-nights were booked with total stay expenditures of CAD 4.9 billion in 2019. The results indicated potential significant disruptions in activities related to tourism; 46% of the buildings investigated have a high to very high vulnerability index. Among them, 4/5 are located in the old city and 1/5 in the downtown area of the pilot zone.

A senior colleague once told me that his life would be ‘dull’ if all a consultant ever did was treat patients. There have been plenty of occasions this winter when I would willingly have traded my yearly salary for a ‘dull life’. Amidst the daily crowd control of Acute Medicine it is easy to immerse oneself in clinical challenges; however it is equally important not to lose touch with management responsibilities during these difficult times. The Economic gloom of the past 12 months will soon have a significant impact on the financial health of the NHS. While Government ministers strive to reassure the Public that the cuts in funding will not impact on patient care, those working in the Service are casting nervous glances over their shoulders, wondering where the axe will fall. It is tempting to believe that the value of the Acute Medical Unit in maintaining patient f low will afford protection from the Chief Executive’s best Hatchet Man. As illustrated in the paper in this edition by Khadjooi and colleagues from Scarborough, early review by an acute medical consultant can be highly effective in preventing unnecessary hospital admission and shortening length of stay. Many readers may be able to produce similar data from local developments within their own units. However, the paper on p 123 shows how changes in funding arrangements might threaten such developments. Alam et al have shown how the lower ‘short stay’ tariff through Payment by Results is far from offset by financial savings from reduced bed numbers. Indeed, hospitals may find themselves losing revenue, discouraging the additional effort which is often required to get patients home sooner. Of course there are other arguments which must not be forgotten – a bed which can be used more than once in 24 hours can attract multiple ‘short stay’ tariffs for the same staff cost; fewer ‘outliers’ in surgical beds mean more ‘high tariff’surgical procedures; the four-hour target would disappear over the horizon if bed occupancy rose any higher; and of course we should not forget the patient, who would surely prefer to sleep in their own bed… Same Sex accommodation has been another hot topic in UK healthcare over recent months. The rapid patient turnover within Acute Medical Units might previously have led acute physicians to consider that they would be excluded from this additional burden. However, recent Department of Health documents make it clear that these ‘rules’ should apply equally on an AMU. Whether this is achievable within our high levels of occupancy will probably depend on the relative levels of priority afforded to each of the targets with which we are faced: is it acceptable to leave a patient on an Emergency Department trolley simply because the appropriate sex bed is not available? Hayley Bonner’s paper on p119 suggests that some patients would probably disagree. Her findings indicate that most AMU patients do not consider this issue as important as some would have us believe; predictably men were less bothered than women, and most would choose a shorter hospital stay above same-sex accommodation if given the choice. Correspondence from readers who have found solutions to these challenges, or on any other issue raised in this edition would be welcomed for future publication.

AbstractThis article begins by looking at the various kinds of secure setting, and the legislation that allows children to be locked up. It moves on to examine, with reference to recent research, the reasons children are detained in secure conditions. The behavioural problems presented by the child, and the social and legal systems which aim to ensure that secure provision is used only when absolutely necessary, have an important bearing on the decision to place a child in secure accommodation. While there is agreement that the use of secure provision is sometimes justified, its use could be reduced through the expansion of appropriate alternative open provision. It is argued that the role of secure provision is still very unclear and poorly managed as a national resource. Secure units often function in isolation and are poorly integrated with other child-care resources. Some young people are moved from placement to placement in an attempt to avoid admission to secure provision, resulting in further damage to themselves and others. There seems to be a failure in the legislation to distinguish between young people who require a short stay in security during a crisis, from those who require a longer stay in an attempt to deal with long-standing antisocial and self-destructive behaviours. This problem has been compounded by the failure to develop an accepted methodology for understanding the behavioural problems presented by this group of young people. The creation of a national agency with specific responsibility for the administration and development of secure provision may help to resolve some of these problems.

PURPOSE Geographical distance to access services and lack of decentralized diagnostic and treatment facilities have been identified as barriers to positive treatment outcomes among cancer patients in Sub-Saharan Africa who have to undergo financial and logistical challenges. Potential approaches to reducing this barrier include providing transport/travel allowance to patients from far flung regions, decentralizing cancer care services or providing patient housing close to cancer treatment facilities. METHODS The International Cancer Institute Child and Family Wellness Center was established in June 2020 as a half-way home for patients undergoing treatment at the ICI Cancer Care and Research Clinic (ICI_CRC). The center aims to provide safe accommodation for patients having challenges to travel to and from their homes for diagnostic work-up and treatment. RESULTS Between June 2020 and October 2021, a total of 101 admissions were made to the ICI Child and Family Wellness Center, of these 76% were female while 24% were male patients. A majority of the patients were first time admissions while 22% of them were admitted more than once; 69% of them were accompanied by a caregiver. The longest duration of stay was 18 days while the shortest was 1 day depending on the reason for admission; the most common being treatment sessions ending late in the day or treatment sessions taking more than one day. The patients admitted were drawn from 15 different counties in Kenya. CONCLUSION Physical inaccessibility to cancer care services in SSA greatly affects patient compliance with treatment and follow-up. Patients who live far from specialist care hospitals are more likely to have an advanced disease at diagnosis, inappropriate treatment, a worse prognosis and poorer quality of life compared to those living closer to hospitals. In addition to decentralization of cancer care, provision of accommodation for cancer patients close to hospitals can greatly improve compliance to treatment resulting in positive treatment outcomes.

The paper focuses on the spatial behaviour of visitors in the context of current megatrends. It aims to identify and characterize the spatial behaviour of the Czech users of the Airbnb service. Firstly, there is a theoretical-methodological and conceptual anchoring of the issue of tourism, mobility,and megatrends. The next part analyses the results of the questionnaire survey. The sociodemographic profile of the respondents is compiled, and the results are confronted with official tourism statistics at the national and international levels. The final findings are discussed in the context of sustainable development. The Airbnb platform is mostly used by the so-called Millennials for trips abroad. The choice of destination corresponds, to some extent, to the most visited countries according to UNWTO statistics. The most frequently chosen mean of transport in the case of outbound tourism is a plane. The main motivation is to spend the holidays. In terms of the number of overnight stays, short stays are generally preferred. This result is related to the fact that most of the destinations are of urban-type and a shorter length of stay is typical for urban tourism. Concerning the sustainability of urban destinations, the uncontrollable concentration of visitors, and the extension of shared accommodation cause socio- economic problems, increase noise, and decrease the quality of residents' life.

The paper focuses on the spatial behaviour of visitors in the context of current megatrends. It aims to identify and characterize the spatial behaviour of the Czech users of the Airbnb service. Firstly, there is a theoretical-methodological and conceptual anchoring of the issue of tourism, mobility,and megatrends. The next part analyses the results of the questionnaire survey. The sociodemographic profile of the respondents is compiled, and the results are confronted with official tourism statistics at the national and international levels. The final findings are discussed in the context of sustainable development. The Airbnb platform is mostly used by the so-called Millennials for trips abroad. The choice of destination corresponds, to some extent, to the most visited countries according to UNWTO statistics. The most frequently chosen mean of transport in the case of outbound tourism is a plane. The main motivation is to spend the holidays. In terms of the number of overnight stays, short stays are generally preferred. This result is related to the fact that most of the destinations are of urban-type and a shorter length of stay is typical for urban tourism. Concerning the sustainability of urban destinations, the uncontrollable concentration of visitors, and the extension of shared accommodation cause socio- economic problems, increase noise, and decrease the quality of residents' life.

This study analyses the impact of short-term study abroad experiences on upper secondary school students’ intercultural competence by means of an experimental design including an intervention and a control group who are studied longitudinally by means of a pre-test, post-test and delayed post-test. In recent years there has been an increasing effort to evaluate the success of study abroad programs not only in terms of number of participants, but in terms of academic, intercultural and linguistic development. Nevertheless, few studies have employed the experimental designs needed to gauge the impact of study abroad programs and even fewer have included a delayed posttest which may shed light on the sustainability of identified effects. The present study includes a broad range of study abroad programs which differ in terms of certain key characteristics, such as duration, type of accommodation or target language. In this way, it is possible to analyse the effect of different parameters on the student’s intercultural development and, ultimately, to identify key factors for successful programs. The paper starts by discussing different models of intercultural competence before outlining the model used in this study. This is followed by a presentation of the participants and the key characteristics of their individual study abroad programs. Analyses of covariance are used to examine the intercultural competence of the students in the control group and the intervention group at the time of the post-test and the delayed posttest and to identify key factors that contribute to the explanation of their intercultural competence. The findings indicate that short-term study abroad experiences have a positive influence on young people’s intercultural competence both short-term and longer-term. The most crucial factors for the explanation of the participants’ intercultural competence are their starting conditions, the duration of their stay, the amount of interaction with representatives of the target culture, and the regular use of the target language. The paper finishes with a discussion of implications for program design and of the limitations of the study.

The freedom of choice by motorists of their route, parking places, the duration of rest, as well as the choice of the type of rest in a complex with the natural resource potential of the Crimean Peninsula determine the advantages of campsites over other accommodation facilities. Crimea has a rich and diverse resource potential of recreation and tourism, which determines the popularity of auto tourism. However, the richness of the natural environment is negatively offset by the low aesthetic level of the territories of car camps themselves, where no work on landscaping and landscaping of places of short-term stay of motorists is often assumed. The variety of climatic zones of the Crimean Peninsula implies an individual approach to the landscaping of parking lots and careful selection of plants that can grow in these conditions with minimal care. During the reconnaissance survey on the territories of objects currently used as car camps on the coast of the Crimean Peninsula, an assessment of landscape features, the degree of landscaping, and compliance with GOST R 58187-2018 "Tourist services" was carried out. Camping sites". In the course of the study, the complete or partial absence of landscaping in the territories of car camps and non-compliance with the requirements of GOST (to varying degrees) was established. The assortment for landscaping of car camps on each of the coasts has been selected, taking into account the main limiting factors.

Objective People with severe mental illness have high rates of hospitalisation. The present study examined the role that permanent housing and recovery-oriented support can play in reducing the number and length of psychiatric hospital admissions for people with severe mental illness. Methods The study examined de-identified, individual-level health records of 197 people involved in the New South Wales Mental Health Housing and Accommodation Support Initiative (HASI) to compare changes in hospitalisation over a continuous 4-year period. Results On average, HASI consumers experienced significant reductions in the number of psychiatric hospital admissions and length of stay after entering the HASI program, and these reductions were sustained over the first 2 years in HASI. Male consumers and consumers under 45 years of age experienced the largest reductions in the number and length of hospital admissions. Conclusions The findings of the present study add support to the hypothesis that supported housing and recovery-oriented support can be effective approaches to reducing hospital admissions for people with chronic mental illness, and that these changes can be sustained over time. What is known about this topic? People living with severe mental illness are heavy users of health and hospitalisation services. Research into the effects of partnership programs on preventing unnecessary admissions is limited because of short periods of comparison and small sample sizes. What does this paper add? The present study extends previous research by analysing de-identified individual-level health records over a continuous 4-year period and showing that reductions in hospitalisation among people with severe mental illness can be sustained over time. What are the implications for practitioners? These findings provide further evidence that community-based recovery-oriented supported housing programs can assist consumers to manage their mental health and avoid hospital admissions. Although the provision of recovery-oriented community services requires an investment in community mental health, the reduction in consumers’ use of hospital services makes this investment worthwhile.

Развитие торговли и экономических связей привело к необходимости строительства специальных заведений, предназначенных для торговцев, путников, с помещениями для вьючных животных. Это в свою очередь привело к появлению постоялых дворов. У каракалпаков постоялый двор назывался шарбақ. Он были двух видов: для кратковременного пребывания, расположенный в черте города недалеко от базара, и долговременного пребывания, устанавливавшийся при въезде в город. Второй из них предпочитали путешествующие издалека. Посетители же первых постоялых дворов останавливались в нем для разгрузки привезенного для продажи товара, реализовав который в течение дня, покидали заведение. Функции шарбақ заключались не только в предоставлении приюта, возможности отдыха, размещения товаров и животных, но и в общении, обмене новостями. В базарные дни сюда стекались жители со всей округи для того, чтобы узнать последние новости. Для старшего поколения шарбақ был, в первую очередь местом проведения досуга. Постоялый двор играл важную роль в жизни каракалпаков. Об этом свидетельствует их количество. К середине XX века постоялый двор начинает терять свою значимость в связи с развитием городской инфраструктуры и появлением гостиниц. The development of economic ties entailed arranging special establishments for traders and travelers, with premises for beasts of burden. This resulted in the construction of hostelries. The Karakalpaks called them sharbak. There were two types of sharbaks: located within the city near the bazaar, intended for a short stay, and installed at the entrance of the city for the long-term visitors. Travelers from far away preferred the second type. Guests of the first type of hostelries usually stayed there just to unload the goods and sell them at the bazaar during the day. The sharbaks not only provided shelter, recreation, and accommodation of goods and animals, but also served as a place for communication and news exchange. On market days, residents from all over the area flocked there to find out the latest news. For the older generation, sharbak was a place of leisure. The hostelry played an important role in the social life of the Karakalpaks, which is evidenced by their large number. By the middle of the 20th century, the sharbak began to lose its significance due to the development of urban infrastructure and modern hotels

The study is relevant due to the necessity to increase the efficiency of socio-psychological adaptation in connection with the growing number of migrants from other countries. The aim of the study is to determine the features of the time perspective in the course of sociopsychological adaptation of forced migrants. The article hypothesizes that time perspective of forced migrants will vary depending on the type of socio-psychological adaptation and on different stages of adulthood. The study sample includes 36 forced migrants who are staying in the temporary accommodation facility in the Belgorod region, aged from 34 to 57 (13 men and 23 women), 21 of them are at the age of early adulthood, 15 are in late adulthood. The methods (tools) of the research are as follows: the “Adaptation of a Personality to a New Socio-Cultural Environment Test” (L. V. Yankovsky) was used to determine the type of adaptation to a new socio-cultural environment; the “Time Perspective Questionnaire” (F. Zimbardo) was applied to study the temporal orientation; a questionnaire was used to fix the socio-demographic status. The study results. At the level of statistical trends, the study proves that early adulthood may be more characterized by an interactive type of adaptation to a new environment, whereas late adulthood may be characterized by a more negative perception of one’s past. The results show that beliefs regarding the time perspective, that prevent the development of a sense of acceptance by the new environment and of the confidence in their capabilities, are characteristic of unproductive adaptation types. The study identifies the attitude to one’s past and the tendency to fatalism of the present as the most significant components of the time perspective for the adaptation process. The author clarifies specific adaptation types and the category of the “productive/unproductive” adaptation types as a whole. The conclusions. Negative perception of one’s past and fatalistic perception of the present are characteristic of unproductive adaptation types (depressive and alienated). A positive attitude to one’s past determines the productive course of socio-psychological adaptation. Among the productive adaptation types, a positive attitude characterizes the adaptive type of inclusion in the new socio-cultural environment. Identification of the time perspective features of forced migrants in the course of their socio-psychological adaptation in the context of a short stay in the country determines the novelty of the issue under discussion. The results obtained can be used in the practice of organizing psychological support for the socio-psychological adaptation of forced migrants.

The hotel industry plays an important role in the modern world of business and tourism. The growing number of international trips, the development of business communications and the increase in demand for comfortable accommodation create prospects for the opening of business hotels. The design of a business hotel is critical to its success and competitiveness in the market. Designing a hotel is a multifaceted task. This is a whole complex of activities: building architecture, interior design and landscaping. All together, it creates a finished image that corresponds to the general idea of the hotel. Designing a hotel requires taking into account many factors: location, capacity, type and class, priority area of activity. The building and territory must strictly comply with sanitary, technical, environmental and other regional norms and rules. When designing city hotels, it is necessary to take into account that the plot should be close to the central part of the city, but preferably not on a noisy street. A great convenience is the proximity of the train station, shopping and cultural institutions. It is very important that there is a park, garden or hotel square nearby. A successful business hotel should have a strategic location, efficient design, high-quality infrastructure and improved services. Demand for hotel buildings increases when cities become attractive to tourists and attract large numbers of visitors. The main design task is to competently place and connect different functional areas in order to, on the one hand, avoid technological problems during the operation of the hotel, and on the other hand, to create a cozy and attractive interior space, as well as beautiful facades , which are remembered. The hotel is a place for short-term stay of guests of the city. It is important that the hotel has the ability to provide various services, such as recreation, holding conferences, organizing business meetings, holding various public events, exhibitions, festivals, press conferences, as well as opportunities for sports and providing communication via telephone and electronic devices. The hotel is the most significant component of the tourism industry and affects the volume of domestic and foreign tourism in the country. The hotel building should attract attention and be remembered. When planning a hotel, it is important to develop a unique concept with an attractive interior and exterior layout. In order to obtain a competitive advantage in the hotel industry, it is necessary to constantly adapt to the changing needs and expectations of customers, to improve the quality of hotel design and construction in accordance with the requirements of the city or country.

One of the many impacts of the Covid pandemic on Canadian cities was the complete collapse of short-term rental (STR) markets, as long-distance travel nearly vanished for more than a year. Many dedicated STRs shifted back to the long-term rental market, but others remained on STR platforms such as Airbnb but with minimum stays of one month or more—a land use we describe as “medium-term rentals” (MTRs). This paper provides a planning analysis of online-platform-mediated MTRs in Canadian cities and their housing-market, land-use, and regulatory implications. First, we identify and explore the regulatory grey zone inhabited by MTRs, which appear to be neither standard residential tenancies nor short-term tourist accommodations. Second, the paper provides a brief empirical overview of the emergence of MTRs during and after the Covid pandemic in Toronto, Montreal, and Vancouver. Third, the paper uses a policy case study of situations in which Ontario’s Landlord and Tenant Board has been asked to adjudicate non-standard tenancies to establish whether there is a planning basis for distinguishing medium-term rentals from other tenancy types. The paper concludes by identifying a key planning principle which could allow Canadian municipalities to pull MTRs out of the regulatory grey zone: regulating type of stay instead of length of stay.

Резиме: Посматрајући искључиво са економског аспекта, не узимајући у обзир етичку или политичку компоненту мигрантске кризе, аргументи о предностима и ризицима великог прилива избјеглица на економију једне земље зависе искључиво од специфичности економског окружења националне економије. Овај рад има за циљ дати процјену могућег економског утицаја избјегличке кризе у Европи, посебно на економију Босне и Херцеговине. У теорији, фискални ефекти имиграције у великој мјери зависе од карактеристика миграната које се односе на њихове вјештине, старост, дужину боравка у земљи домаћина, а који утичу на њихово учешће на тржишту рада и социјална права. Процјене фискалног утицаја имиграције су ограничене усљед недостатка података и тачних информација о широком спектру важних фактора који утичу на процјену. Због наведених разлога, изучавање ефеката у овом моменту заснива се на великом броју претпоставки које се морају узети у обзир у циљу предвиђања резултата. Истраживање смо спровели на хипотетичком сценарију већег прилива миграната у БиХ, који би под наведеним околностима имало одређеног утицаја на фискалну економију. Резултати истраживања показују да би се у кратком року повећало јавно трошење које произилази из тако великих токова миграција, али би за развијене земље Европе у дугом року такође могло бити и економских предности, под условом да се избјеглице адекватно интегришу на тржиште рада. Уколико би дошло до већег прилива миграната у Босну и Херцеговину, утицај на нашу економију првенствено би се огледао у ефектима на јавне финансије и тржиште рада. Раст јавних расхода за издатке смјештаја, прихвата избјеглица и социјална права, могућ пораст сиве економије што би посљедично довело до пада јавних прихода уз истовремено већу незапосленост усљед веће понуде радне снаге, представљало би значајан изазов за јавне финансије Босне и Херцеговине.Summary: Observing from an economic point of view, without taking into account the ethical and political component of the migrant crisis, arguments about the benefits and risks of large inflow of refugees to a country’s economy, dependent basically on the specifics of the economic environment of the national economy. This paper aims to provide an assessment of the potential economic impact of the refugee crisis in Europe, especially on the economy of Bosnia and Herzegovina. In theory, the fiscal effects of immigration largely depend on the characteristics of migrants related to their skills, age, length of stay, and affecting their participation in the labor market and social rights. Estimates of the fiscal impact of immigration are limited by lack of data and accurate information on a broad range of important factors that affect the estimates. For these reasons, the study of effects at this point is based on a number of assumptions that must be taken into account in order to assess the fiscal effects of immigration, and the results tend to change based on these assumptions. Therefore, we conducted a survey on the hypothetical scenario of massive inflow of migrants in BiH, who under these circumstances had the most impact on the fiscal economy. The research results show that there will be short-term costs arising from such a large migration flows, but for the developed countries of Europe in the long term also be economic benefits, provided that the refugees integrate into the labor market. Should there be a large inflow of migrants in Bosnia and Herzegovina, the impact on our economy would primarily be reflected in the effects on public finances and the labor market. Increased unemployment due to higher labor supply, the growth of the grey economy which would consequently led to a decline in public revenues while increasing public expenditure for expenditures for social rights, and accommodation and reception of refugees, would constitute a significant challenge for the public finances of Bosnia and Herzegovina.

The tourist arrivals were growing from 2012 to 2019, and 1.8 million people visited Armenia in 2019. That number was not surpassed in subsequent years, and the expenditures by international inbound visitors amounted to about 2.44 billion US dollars in 2022 (accounting for 12.5% of GDP). The article attempts to identify the role of expenditures by international inbound visitors in Armenia in explaining the statistically significant changes in the real gross domestic product (GDP), and the role of tourist arrivals and exchange rate in explaining statistically significant changes in tourism receipts in the short run utilizing the least squares estimation techniques and using quarterly data (2012q1-2023q2); and how vulnerable the Armenian economy is to external shocks to propose respective recommendations on priorities to address the challenges faced under various scenarios we built. We find evidence of the «multiplier effect» with respect to tourism receipts and conclude that the Armenian economy is vulnerable to changes in tourist arrivals (especially visitors from Russia). The slight reduction in tourist arrivals from Russia or if their number remains unchanged could be accompanied by a decrease in expenditures by Russian visitors in Armenia in the period 2024-2026. We conclude that the overvalued Armenian dram against the US dollar in the short run and medium term would negatively affect the price competitiveness of Armenia as an attractive travel destination for foreign visitors unless Armenia succeeds in offering specific tourism products by taking into account the price-perceived quality ratio to attract foreigners. We emphasize the importance of the availability of 2-star hotels or affordable accommodation in the medium term to prevent a drop in tourist arrivals if the Armenian dram remains overvalued.

The Ukrainian economy and the tourism sector are experiencing the biggest crisis in recent decades. Inbound tourism practically ceased to exist. Due to the war between Russia and Ukraine, the holiday season was not opened this year either on the Sea of Azov or the Black Sea. The war destroyed the holiday season by 90%. A large part of the sea coast is occupied by the enemy, and in places where there is access to the sea, the risk of shelling and mines remains. Odesa regional military administration and Odesa city hall decided not to open sea beaches - due to mine danger. The mining of the Black Sea is a huge problem for both people and the environment, now there are several hundred mines in the water area - up to six hundred and some of them are Ukrainian, stolen in Sevastopol by the Russians back in 2014 after the occupation of Crimea. Travel companies in Ukraine almost completely stopped business on February 24. Air flights stopped and hotels accepted displaced people. The tourism industry, which, according to the State Statistics Service, brought 3% of GDP to the budget of Ukraine, and according to expert estimates, up to 7%, has suffered almost the biggest losses since the beginning of the war. In addition to the absence of vacationers, losses are also caused by enemy ammunition. Russian mines hit the shores of the sea, detonating and damaging first-line recreation centers, cafes and bars. In May of this year, it was planned to allow tourists to sunbathe on some beaches and began actively offering accommodation services. However, at dawn on June 6, it became known about the partial destruction of the Kakhovskaya HPP dam The destruction of the dam led to a huge ecological disaster. As a result of the detonation, a huge area was flooded - tons of dirt, poisonous substances along with the ruins of buildings and thousands of dead animals were carried into the Black Sea. Tourists who came to the sea a few days before the explosion of the Kakhovskaya HPP witnessed frogs jumping out of the sea, wild ducks swimming, trees and driftwood. Here and there there were islands of reeds on the shore. There were green spots on the surface of the water. After what they saw, vacationers began to cancel hotel reservations en masse and returned home. At the same time, losses to the hotel business amounted to hundreds of thousands of hryvnias. Between the cities of Yuzhne and Koblevо, there are 29 tourist accommodation facilities. These are collective accommodation facilities located in the recreation area of the village. Sychivka, each of which can accommodate 200 people on average. Sychavka is a village in the Lymanskyi (Cominternivskyi) district of the Odesa region, which is located on the shore of the Black Sea. The main advantages of recreation in Sychavka are the proximity of the Black Sea, a sandy beach strip, a gentle descent into the sea convenient for children, and the complete absence of industrial enterprises. There are no five-star hotels in Sychavka, but there are several recreation centers right on the shore of the Black Sea. If desired, vacationers can rent rooms in detached houses or cottages. According to preliminary estimates, the economic losses from the disruption of the tourist season in this area amount to approximately 300,000,000 hryvnias.

The number of forcibly displaced persons in the world is on the rise, and the escala¬tion of the conflict in the territory of Ukraine has contributed significantly to this increase. According to UNHCR estimates, more than 6.8 million people fled from Ukraine to European countries, and more than 6.6 million were displaced within Ukraine itself. The greatest burden of caring for displaced persons from Ukraine is borne by the neighbouring countries. The situation caused strong condemnations of Russian aggression and widespread expressions of solidarity with the humanitarian disaster, both in the EU and in the Republic of Croatia. In order to provide shelter and support to displaced persons, states have to use numerous resources of their national public administrations. The ability of a public administration to manage the reception and care of a large number of displaced persons can be viewed through the prism of administrative capacity, understood as a set of skills and competencies that a public administration acquires and uses in its work in order to facilitate and contribute to solving problems at the level of the en¬tire administrative system or individual administrative organisations. In the context of the discussion about the problem-solving capacity of state and non-state actors involved in governance, Lodge and Wegrich (2014) consider the ways of using state resources and their connection with administrative capacities. For this purpose, they distinguish between four types of administrative capacity – regulatory, delivery, co¬ordination and analytical. The paper analyses the response of Croatia to the mass influx of displaced persons from Ukraine since the escalation of the conflict in February 2022. The analysis was based on the concept of administrative capacity, applied to the reception and care of a large number of persons in humanitarian crises, and on the obligations of Croatia under the EU Temporary Protection Directive. This Directive regulates various obligations of EU member states in the event of the activation of temporary protection and the provision of a number of rights to displaced persons for the duration of the protection. The subjects of analysis are policy documents, regulations governing this area and the practice of public authorities. The paper is divided into four parts. The introductory part provides a general over¬view of the situation and statistical data on the number of people displaced from Ukraine, as well as an overview of the temporary protection institute as governed by EU regulations. It also states the purpose, subject and expected contribution of the paper. The second part provides a brief overview of the legal regulation of temporary pro¬tection in the context of the Croatian asylum system and analyses Croatia’s approach to aggression against Ukraine based on the most important documents of the key branches of government, the Croatian Parliament and the Government of the Repub¬lic of Croatia. Temporary protection is regulated within the framework of the Act on International and Temporary Protection, i.e., it is included as a kind of third form of protection within the asylum system. In practice, however, since the beginning of the acceptance of displaced persons from Ukraine, a clear distinction has been made according to the system of international protection (including asylum and subsidiary protection), both in terms of simplifying procedures and in relation to the authorities competent for coordinating the temporary protection system. The central part of the paper provides an overview of the administrative capacities of the Croatian public administration (at state and local levels) for implementing the legal institute of temporary protection in practice. Regulatory capacity refers to the ability to make timely decisions, regulations, strategic documents and other general and individual acts, at the state and local level, and the use of various instruments for better regulation. The results indicate that the regulatory framework in Croa¬tia was established in a remarkably short time, based on the coordinated action of key stakeholders who were tasked with implementing measures for the reception and care of displaced persons from Ukraine. Competent ministries timely and ad¬equately informed the bodies under their jurisdiction about the content and implementation method of measures for the successful reception and care of displaced persons, issued decisions and instructions, and tasked other state administration bodies to regulate more closely the area of their activities related to the reception and care of displaced persons from Ukraine. Delivery capacities refer to the provi¬sion of services in certain sectors, that is, the implementation of certain rights from the scope of temporary protection in practice. The paper showed that, in a very short period of time, the competent ministries sent operational instructions to their de¬partments involved in the implementation of measures related to the reception and care of persons under temporary protection. The website “Croatia for Ukraine” was established in order to provide general information to displaced persons, stakeholders involved in the reception and care system, as well as citizens. Besides, a number of local self-government units took various additional measures to facilitate the re¬ception and stay of displaced persons in their communities. Coordination capacity includes connection and cooperation between various sectors (horizontal) and levels of government – local, regional, central, and European (vertical). Very quickly, various coordination mechanisms were established, which laid the basis for the efficient implementation of measures for the reception and care of displaced persons. Ana¬lytical capacity refers to the ability of a public administration to evaluate its system, predict future development and, as much as possible, supervise the implementation, data collection and development of mechanisms for planning, monitoring and evaluating the results of public policies and comparing achieved and planned goals and measures. The conflict in Ukraine and the consequent flight of the population is of a crisis nature, so it is not possible to fully predict the extent of the capacity to receive and care for people because it is not possible to foresee the number of people who will request temporary protection in Croatia, or the duration of the conflict, i.e., the dynamics of the return of displaced people to Ukraine or their departure to other EU member states. Furthermore, the relatively short period of time that passed from the escalation of the conflict to the moment of writing this paper affects the possibility of evaluating planned and achieved goals and measures. Therefore, the analytical capacity is analysed in relation to the following indicators: the collection and availability of statistical data on the number of displaced persons, the relationship between the influx of persons and the preparation of accommodation facilities, and the evaluation of the achievement of goals and measures based on the awareness of displaced persons about the rights granted under temporary protection and problems in exercising those rights. The fourth part includes concluding considerations. It is concluded that the admin¬istrative capacities of the Croatian public administration for implementation, regula¬tion and coordination proved to be sufficient for a timely and appropriate response to this type of humanitarian crisis. However, considering that only a few months have passed since the activation of temporary protection, it is too early to draw conclusions about the connection between the planned goals and measures and their practical delivery as monitoring and evaluation mechanisms are generally less developed in the Croatian public administration. It is concluded that several factors contributed to the quick and effective action of the competent authorities: solidarity with Ukraine and condemnation of Russia by all political bodies in Croatia and the EU, the proximity of the conflict, the demo¬graphic similarity of displaced persons and the local population, the experience of the Croatian War of Independence, and the general support of the Croatian citizens for helping displaced persons.

Shortly before the premiere of Cavalleria rusticana, Pietro Mascagni cut 246 measures from his opera. This substantial section of music has remained largely unknown and has never been examined. Recent access to the original prompter's score, the score once in the possession of the first conductor (Leopoldo Mugnone), autograph letters, unexplored reviews, and a rediscovered staging manual have made a thorough evaluation of the cuts possible. These cuts fall into three categories: (1) those tightening the pace, (2) those reducing the taxing part of the chorus, and (3) those accommodating transpositions requested at the last minute by the star singers Gemma Bellincioni (Santuzza) and Roberto Stagno (Turiddu). The article argues that the cuts had consequences beyond their originally intended function, affecting the staging, drama, and formal conception. In the “Introduzione,” for instance, they lead to confusion about the way in which the scene should be staged; in the “Sortita di Alfio,” they eliminate music that functioned as the culmination of the aria's large-scale formal plan; and in the composite No. 5, they exaggerate the so-called dramaturgy of harsh junctures. In short, these cuts shed important light on the composer's original dramatic intentions and technical aspirations, and have lingered for over one hundred years without being considered for reinstatement.

Learning outcomes This case study aims to yield the following learning outcomes: understand the key performance indicators of successful human resource management (HRM) in the hospitality and tourism sector, especially during pandemics; identify the various concepts and strategies of HRM and recruitment over a short period; conceptualize the types of HRM practices such as safety and health, recruitment and promotion and rewards when facing pandemic conditions as well as the handling of hotel staff in strained times; evaluate the crisis management solutions used by human resources to lower the employee turnover rate; and develop a crisis management plan from a human resource standpoint in a pandemic situation. Case overview/synopsis A five-star hotel in Abu Dhabi, United Arab Emirates (UAE), Bab Al Qasr Hotel & Residence (BAQHotel) opened in October 2016. In April 2020, the hotel began accepting patients with COVID-19 in conjunction with the Abu Dhabi’s Healthcare Company (SEHA), as a support to the UAE Government, through Department of Culture and Tourism Abu Dhabi (DCTAD), to meet the local needs and sustain business during these unforeseen circumstances, which heavily impacted the whole World. Samer Majari, the Human Resource Director of BAQ hotel was responsible for recruiting and supervising delegates, while ensuring the comfort of hotel staff, arranging for their transportation, catering, safety and well-being. To combat the high staff turnover, including COVID-19-positive staff, Majari reviewed the existing staff model; divided the staff into two groups for providing services to both sides of the hotel; arranged for separate accommodations, food and transportation; and retained the existing resources and recruited new workers. This study aims to provide management solutions that concern hiring of staff from the existing UAE market and highlights ways of creating a lower staff turnover rate through incentives and compensations, while also managing staff by motivating them and also safeguarding them against COVID-19. Complexity academic level This case study intends to provide a context for creative solutions to human resource challenges facing organizations during a pandemic. It also involves swift responses to crises faced by HR managers and the immediate solutions required. Therefore, this case study can be used in undergraduate level courses for students pursuing a bachelor’s or a master’s degree in HRM, hospitality management, crisis management or international business studies. Moreover, this case study can be used for corporate training and to help hospitality industry staff, mid-level human resource managers and organizational development practitioners to better understand crisis management in their hotels. Supplementary materials Teaching notes are available for educators only. Subject code CSS 6: Human Resource Management

Dear Editor, Nursing education consists of classroom and clinical training to demonstrate clinical competence based on theoretical concepts learned. However, there is a lack of clinical abilities demonstrated and theoretical knowledge gained from pre-qualified nursing education and the preparation of new graduates. Furthermore, graduates often believe that the lessons learned do not reflect the actualities faced in clinical fields. This discrepancy is known as the theory-practice gap among graduate nurses who are theoretically but not practically equipped to apply theory and knowledge to practice in the clinical environment. Graduate nurses working in high-risk fields can struggle to integrate theoretical concepts into the clinical environment, leading to patient safety risks and potential adverse outcomes. Furthermore, the new graduates experience a deficit that contributed to decreased job satisfaction, increased job turnover rates, and patient care mistakes. This paper aims to address the gap between nursing education and practice in the nursing profession. The nurse’s role has grown substantially in recent years due to the shift in patients’ medical needs. Nurses are no longer just the “bedside healers” who hand you your medication and make sure your bedpan is clean, and they are also critical components of your healthcare team. The shift in inpatient medical needs requires more than just bedside healers. Nurses want to work on the skills needed for clinicians. Nurses need to take any opportunity they can get to stand out more than ever (1). Over the past 30 years, nurses’ education has been shifted from hospitals to universities. The theory part has begun to gain greater popularity in nursing education. Literature shows a clear gap between classroom teaching and student nurses’ experiences in clinical areas (2). Nurses are essential to excellent health care at all levels and provide complex patient services in different facilities. These services are only provided if the nursing profession has excellent clinical knowledge of nursing and can meet the needs of many different public health services. In view of the needs of the general public, new graduate nurses must be educated and equipped to use the clinical skills needed after nursing school with confidence. However, clinical competence is only part of providing excellent health care, and new graduate nurses must make the best clinical judgment for patients (3). Nursing is a holistic approach involving caring for people with compassion, but it has changed because patients expect to be treated quickly and transferred to the next. In addition, nurses face challenges because they are challenged in clinical fields and do not have the necessary capacity to cope with daily situations (4). Therefore, this article aims to review the gap between theory and practice in the workplace nursing profession. It is important to think about the differences between theories and practices. As defined by dictionaries, a theory is a set of statements or principles devised to explain a group of facts or phenomena, especially one that has been repeatedly tested or is widely accepted and can be used to make predictions about natural phenomena. Practice is defined as the act or the process of doing something, performance, or action. In definition, these terms appear to be at odds with each other, but when considered in terms of professional setup, they have to enable the application of ‘applying the theory into practice’(5). New graduate nurses face challenges transitioning from school to clinical training, affecting their performance. These challenges include knowledge level, physical demands, social acceptance stress from colleagues, and adaptation to new working environment culture. Concern about nurses’ competence stems from the rise in-hospital mortality rates in the United States. New and experienced nurses are highly expected to provide effective and safe patient care. There is still no clear answer to whether the new graduate nurses lack the appropriate education or if there is excessive pressure on the schools to quickly graduate a larger number of nurses to fill the increasing need for nurses in the clinical environment. The transition from nursing student to nurse work has proven to be a difficult transition that many researchers have studied. Some studies show that new graduate nurses lack the necessary skills to play the role of nurses without clinical experience. New graduate nurses are faced with many different challenges and intense pressures to meet the expectations of their profession. The nursing education programme encourages professional nurses to integrate theory and practice to provide high-quality nursing care in practice. Practical learning allows nurses to provide nursing care based on their knowledge. Nursing is an important field where knowledge is applied after education to practical skills. The distinction between theory and practice is one of the many topics of nursing discussion issues, such as the unresolved threads of a long time (6). Though nurses have been required to do more than ever before, the way they prepare for and embark on this career path has remained unchanged. According to a survey, 83% of new graduate nurses did not receive any formal training in their profession before starting work. A survey has found that 80% of nurses believe that this is a problem in their workplace (7). 90% have expressed the intention to work one or more additional days as they describe as ‘clinical application’ days. A gap has been found between the educational experience and the level of competence required by the clinical setting. Nursing students need to be prepared for various clinical settings where they will be called on to use a wide range of skills and techniques (8). The nursing programs lack clinical skills, but the issue stems from what is being taught to the students. For example, nurses are not learning how to keep infections out of hospitals by washing their hands properly. Students have not gained the necessary knowledge because they are being taught about theory rather than clinical practice. Another issue is that teachers have difficulty keeping up with the fast-paced changes in nursing because they were trained before many of these changes occurred (9). The new generation of nurses lacks adequate on-the-job training due to the uncertainty of getting a job offer after finishing their course. Nurses are also not given enough time on-site with patients during their graduate studies for practical experience (10). This is because patients are generally only admitted for short periods during their stay at hospitals or nursing homes. There is a considerable gap between the skills required from a nursing student to provide clinical skills. A nursing student needs to know pre-hospital, hospital, home care, treatments, associated procedures, and first aid. This gap could be due to insufficient preparation for clinical scenarios or not nursing educators practicing these skills. The solution should provide sufficient clinical skills preparations for nursing students, engage teachers to practice these skills, and engage clinical professionals to participate in the education of the students (11). In this regard, organizations such as the International Laboure Organization (ILO) endorsed articulation arrangements allowing post-secondary students across countries to access top traditional higher education. However, though other academic institutions offer certificates or diplomas in nursing assistant studies, not all of them have been recognized by ILO. Others push to improve the training opportunities by increasing the hours of accommodation visits, block releases, and summer programs to see long-lasting changes. Nurses should start preparing for the workplace before they graduate. That way, they can be more prepared for these future challenges. Primarily focus on supporting collaboration between academics and clinicians, establishing a research culture in a clinical environment, and improving access to research. In order to do so, practitioners need access to current information, learning resources, and opportunities for continuous education. The theory-practice gap, it would seem, is a multifaceted problem. The most common reasons included that the theory was about building a knowledge base while practice was about learning nursing skills. Education is an essential element of the preparation of nurses for real situations. However, education must include theory and nursing practice, and the teaching of excellent teachers in these two areas is linked (12). New graduate nurses must be confident and prepared to take on a role that will life-changing environment. Nurses are stressed because nurses know that the health of patients is dependent on good care. Research in this field is essential to ensure the workforce is equipped with the best-qualified nurses. Thus, overall, it is quite evident that the gap exists and has areas that can be improved. Strategies for solving this problem include re-examining the curriculum and liaising between education and practice. In education and clinical environments, leaders and followers will create operational plans for this proposed model and link it to benefits to make nursing professionals beneficial at large.

Abstract Background: Bromodomain and extra-terminal domain (BET) family proteins represent a novel target class for patients (pts) with myeloid malignancies. Pharmacologic inhibition of BET proteins transcriptionally downregulates critical pro-survival and anti-apoptotic genes. We hypothesized that combination of BET inhibitor (BETi) with hypomethylating agent (HMA) azacitidine (AZA) could lead to clinical benefit for high-risk (HR) pts with R/R MDS and AML. Methods: We conducted an investigator-initiated, single-center, phase I, 3+3 dose-escalation and cohort expansion study of PLX51107 (BETi) + AZA in pts with R/R HR MDS (intermediate-2 score or >10% blasts) or R/R AML. PLX51107 was administered PO on days 1-21 and AZA 75 mg/m2 IV on days 8-14 of a 28-day cycle. Dose-escalation phase of PLX51107 doses included: 40mg (n=4), 80mg (n=3), and 120mg; ultimately, no formal MTD was reached, therefore the 120mg dose was administered to the remaining 30 pts treated on study. Results: 37 pts were treated [R/R AML (n=33); R/R HR MDS (n= 4)]. Baseline characteristics included in Table. Median age was 64 years [18-85 years]. 51% female. Baseline cytogenetics: Notably, 18 pts (49%) had chromosome (chr) 3 abnormalities (abnl) [(either alone or with complex cytogenetics) with 15/18, or 89%, + for EVI1/MECOM gene rearrangement by FISH. 81-gene panel Next Generation Sequencing (NGS) showed: NRAS (n=11); TP53 (n=9); ASXL1, PTPN11, RUNX1, SF3B1, & WT1 (n=6 each). Median prior # therapies = 3 [1-9]; 97% had prior HMA therapy; 84% had prior venetoclax (VEN).17 (46%) pts had prior stem cell transplant (SCT); 7 of whom were on concurrent active immunosuppressive therapy for GVHD prophylaxis at time of enrollment and continued on study (n=6 tacrolimus; n=1 sirolimus). 9 had prior myeloproliferative neoplasm (MPN) or MDS preceding AML. 16 (43%) had prior malignancy (including lymphoma n=3). Toxicities: Median # cycles on therapy = 2 [1-19+]. Most common grade 1/2 non-hematologic toxicities: fatigue 3%; cholecystitis 3% and vomiting 3%. Notable grade 3/4 non-hematologic toxicities: 9 (24%) pts had elevated bilirubin/liver function tests (n=2 Grade 4 and n=7 Grade 3) and n=24 had infections. Hematologic toxicities were n=7 (4 Grade 3, 3 Grade 4) anemia; n=6 (all Grade 4) thrombocytopenia, n=3 (2 Grade 3, 1 Grade 4) neutropenia. Outcomes: Overall Response Rate (ORR) = 8/37 (22%): complete remission with incomplete platelet counts (CRp) (n=1); morphological leukemia-free state (MLFS) (n=2) (both MLFS responders had chr 3 abnl); hematologic improvement (HI) (n=5). Additionally, 5 other pts had >50% bone marrow blast reduction. 4 pts were able to stay on study ≥6 months, with one patient staying on active therapy with ongoing clinical benefit for ≥1 year (16.7 months+). Notably, 10/13 (77%) of all of these responding pts occurred in prior VEN-treated pts. 6/13 (46%) of all responses occurred in RUNX1 or NRAS/KRAS family-mutated pts. Median time on study was 4.8 months [0.4-16.7]. Median overall survival was 3.6 [0.4 - 16.7] months (Figure). One remarkable responder, a 70 year-old woman with R/R AML and extensive leukemia cutis, (prior VEN-based therapy), achieved CRp and almost complete resolution of all skin lesions with no major toxicities after 3 cycles of therapy. Laboratory correlative analysis: RNA-Seq analysis of mononuclear cells harvested on- treatment (day 3) vs pre-treatment demonstrated markedly greater fold changes in mRNA expressions in the complete responders, with downregulation of MYC, BCL2, IL7R and CDK6 genes and upregulation of HEXIM, CD93, DCXR and CDKN1A genes. Immunoblot analyses confirmed reduction in the protein levels of c-Myc, CDK6, BCL2 and BCL-xL and induction of BRD4 and HEXIM1 protein levels in the responding pts. Conclusions: In a heavily pre-treated, high-risk group of pts with R/R HR MDS and AML, with 49% chr 3 abnl, 46% prior SCT, and 25% TP53-mutated, we demonstrate that the combination of BETi and HMA is safe, well-tolerated, and results in modest clinical benefit predominantly in prior VEN-treated pts. Future directions may include investigation of novel BETi combinations in VEN-naïve pts, further investigation into high-risk subsets of pts with chr 3 abnl/EVI1/MECOM rearrangements, RUNX1, and RAS-family mutated pts, and further clinical/translational investigation of BETi activity in leukemia cutis/skin lesions in myeloid malignancies. ClinicalTrials.gov Identifier: NCT04022785. Figure 1 Figure 1. Disclosures Pemmaraju: Sager Strong Foundation: Other; Samus: Other, Research Funding; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; Plexxicon: Other, Research Funding; Daiichi Sankyo, Inc.: Other, Research Funding; Cellectis S.A. ADR: Other, Research Funding; CareDx, Inc.: Consultancy; Aptitude Health: Consultancy; Springer Science + Business Media: Other; DAVA Oncology: Consultancy; Roche Diagnostics: Consultancy; MustangBio: Consultancy, Other; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Celgene Corporation: Consultancy; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; LFB Biotechnologies: Consultancy; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; Incyte: Consultancy; Affymetrix: Consultancy, Research Funding; Protagonist Therapeutics, Inc.: Consultancy; Clearview Healthcare Partners: Consultancy; Blueprint Medicines: Consultancy; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Daver: Abbvie: Consultancy, Research Funding; Novartis: Consultancy; Hanmi: Research Funding; Genentech: Consultancy, Research Funding; Sevier: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Trovagene: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Amgen: Consultancy, Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; Glycomimetics: Research Funding; Novimmune: Research Funding; Pfizer: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. Ravandi: Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Research Funding; Xencor: Honoraria, Research Funding; Novartis: Honoraria; AstraZeneca: Honoraria; AbbVie: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Taiho: Honoraria, Research Funding; Astex: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Prelude: Research Funding. Kadia: AstraZeneca: Other; Genfleet: Other; Astellas: Other; Cellonkos: Other; Ascentage: Other; Sanofi-Aventis: Consultancy; Pulmotech: Other; Pfizer: Consultancy, Other; Novartis: Consultancy; Liberum: Consultancy; Jazz: Consultancy; Genentech: Consultancy, Other: Grant/research support; Dalichi Sankyo: Consultancy; Cure: Speakers Bureau; BMS: Other: Grant/research support; Amgen: Other: Grant/research support; Aglos: Consultancy; AbbVie: Consultancy, Other: Grant/research support. DiNardo: GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Forma: Honoraria, Research Funding; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding; Foghorn: Honoraria, Research Funding; AbbVie: Consultancy, Research Funding; Agios/Servier: Consultancy, Honoraria, Research Funding; Novartis: Honoraria; Takeda: Honoraria; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Research Funding; ImmuneOnc: Honoraria, Research Funding. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. Burger: Beigene: Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; AstraZeneca: Consultancy; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Short: Novartis: Honoraria; NGMBio: Consultancy; Jazz Pharmaceuticals: Consultancy; AstraZeneca: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Amgen: Consultancy, Honoraria. Alvarado: Astex Pharmaceuticals: Research Funding; BerGenBio: Research Funding; CytomX Therapeutics: Consultancy; Daiichi-Sankyo: Research Funding; FibroGen: Research Funding; Jazz Pharmaceuticals: Research Funding; MEI Pharma: Research Funding; Sun Pharma: Consultancy, Research Funding. Jain: TG Therapeutics: Honoraria; Beigene: Honoraria; Precision Biosciences: Honoraria, Research Funding; Incyte: Research Funding; Adaptive Biotechnologies: Honoraria, Research Funding; Cellectis: Honoraria, Research Funding; ADC Therapeutics: Honoraria, Research Funding; Pfizer: Research Funding; AstraZeneca: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Pharmacyclics: Research Funding; Janssen: Honoraria; Fate Therapeutics: Research Funding; Aprea Therapeutics: Research Funding; Servier: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding. Verstovsek: Promedior: Research Funding; PharmaEssentia: Research Funding; NS Pharma: Research Funding; Ital Pharma: Research Funding; Incyte Corporation: Consultancy, Research Funding; Gilead: Research Funding; Genentech: Research Funding; CTI BioPharma: Research Funding; Celgene: Consultancy, Research Funding; Blueprint Medicines Corp: Research Funding; AstraZeneca: Research Funding; Novartis: Consultancy, Research Funding; Protagonist Therapeutics: Research Funding; Roche: Research Funding; Sierra Oncology: Consultancy, Research Funding; Constellation: Consultancy; Pragmatist: Consultancy. Issa: Novartis: Consultancy, Research Funding; Kura Oncology: Consultancy, Research Funding; Syndax Pharmaceuticals: Research Funding. Khoury: Kiromic: Research Funding; Angle: Research Funding; Stemline Therapeutics: Research Funding. Konopleva: Ablynx: Other: grant support, Research Funding; Agios: Other: grant support, Research Funding; Ascentage: Other: grant support, Research Funding; Calithera: Other: grant support, Research Funding; AstraZeneca: Other: grant support, Research Funding; Forty Seven: Other: grant support, Research Funding; Cellectis: Other: grant support; F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support; Rafael Pharmaceuticals: Other: grant support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding; Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding; Genentech: Consultancy, Honoraria, Other: grant support, Research Funding; Stemline Therapeutics: Research Funding; Sanofi: Other: grant support, Research Funding; Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights; Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights; KisoJi: Research Funding. Kantarjian: Astra Zeneca: Honoraria; Aptitude Health: Honoraria; Jazz: Research Funding; Daiichi-Sankyo: Research Funding; Astellas Health: Honoraria; Ipsen Pharmaceuticals: Honoraria; AbbVie: Honoraria, Research Funding; Ascentage: Research Funding; Amgen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Immunogen: Research Funding; BMS: Research Funding; KAHR Medical Ltd: Honoraria; NOVA Research: Honoraria; Precision Biosciences: Honoraria; Taiho Pharmaceutical Canada: Honoraria. Borthakur: Takeda: Membership on an entity's Board of Directors or advisory committees; ArgenX: Membership on an entity's Board of Directors or advisory committees; Ryvu: Research Funding; Astex: Research Funding; University of Texas MD Anderson Cancer Center: Current Employment; Protagonist: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy.

Abstract Background: FL is an indolent yet incurable disease characterized by recurrent relapses. Pts with R/R FL often have a poor prognosis and limited treatment options, particularly those who have progression of disease within 24 months of frontline treatment (POD24) or are refractory to multiple agent classes. Glofitamab is a T-cell-engaging, CD20xCD3 bispecific, full-length, 2:1 format antibody with bivalent binding to CD20 (B cells) and monovalent binding to CD3 (T cells). Glofitamab monotherapy with obinutuzumab pretreatment (Hutchings, et al. JCO 2021), or combined with obinutuzumab (Morschhauser et al, Blood 2019; NCT03075696), has shown efficacy and manageable safety in heavily pretreated R/R NHL. Here, we present updated results of glofitamab with three different step-up dosing (SUD) regimens as monotherapy (mono) or combined with obinutuzumab (combo) in R/R FL. Methods: Obinutuzumab (1000mg) was given 7 days prior to the first dose of glofitamab. For the 3 mono cohorts, intravenous glofitamab SUD was given on Days (D) 1 and 8 of Cycle (C) 1; then at target dose on C2, or as SUD on C1D1, C1D8, C2D1 and target dose on C3D1. For the combo cohort, glofitamab SUD was given on D1 and D8 of C1, then at target dose combined with obinutuzumab 1000mg from C2D1 and onwards (every 21 days for up to 12 cycles). Response rates were based on the Lugano criteria (Cheson et al. J Clin Oncol 2014). Results: As of May 18, 2021, 53 pts received glofitamab mono SUD (2.5/10/16mg, n=3; 2.5/10/30mg, n=21; 0.5/2.5/10/30mg, n=29) and 19 pts received glofitamab combo SUD (2.5/10/30mg). All pts had FL Grade (Gr) 1-3A (FLIPI 1 high risk score: mono, 28 [53%] pts; combo, 11 [58%] pts). Median age was 64 years (range 33-83) in mono cohorts and 61 years (range 41-78) in the combo cohort; median number of prior therapies was 3 (range 1-12) and 2 (range 1-5), respectively. Twenty-eight (53%) pts in the mono cohorts and 8 (42%) pts in the combo cohort were refractory to last therapy; 16 (30%) and 7 (37%), respectively, were refractory to prior CD20 and alkylating therapy (double refractory). A total of 19 (36%) pts in the mono cohorts and 10 (53%) pts in the combo cohort had experienced POD24. In the mono cohorts, overall response rate (ORR) was 81% (n=43) and complete metabolic response rate (CMR) was 70% (n=37), with 72% (n=21) CMR in the 0.5/2.5/10/30mg cohort and 67% CMR in both the 2.5/10/16mg (n=2) and 2.5/10/30mg (n=14) cohorts. In the combo cohort, ORR was 100% (n=19) and CMR was 73.7% (n=14). In the mono cohorts 87% (32/37) pts were in CMR, while in the combo cohort 71% (10/14) pts were in CMR. Median follow-up of CMR ranged from 0-14 months (mono) and 0-5 months (combo), and at this cut-off the follow-up is insufficient to assess CMR duration. High CMR rates were observed in high-risk pts (Table). The most common adverse event (AE) was cytokine release syndrome (CRS): 66% and 79% in the mono and combo cohorts, respectively. CRS rates by mono cohort were as follows: 2.5/10/16mg cohort, 100% (3/3); 2.5/10/30mg cohort, 76% (16/21); 0.5/2.5/10/30mg cohort, 55% (16/29). With mono, CRS events (Lee et al. ASTCT 2019) were mostly Gr 1 (47.2%) and 2 (17.0%); 1 pt had a Gr 3 event (2.5/10/16mg cohort). With combo, 52.6% had Gr 1 CRS and 26.3% had Gr 2 CRS. There were no Gr 3 CRS events in the combo cohort and no Gr 4 or 5 CRS with either regimen. Of pts with CRS, tocilizumab was used to treat CRS in 22.9% pts in mono cohorts and 33.3% pts in the combo cohort. All CRS events were manageable and had resolved at data cut-off. Neurologic AEs were seen in 26 pts (16 mono, 10 combo; 36%); all Gr 1 (n=17) or Gr 2 (n=9). No ICANS-like events related to glofitamab were reported. Other common AEs were infusion related reactions and pyrexia (events separate from CRS; both 28%) and neutropenia (26%) with mono, and neutropenia (58%), anemia (37%) and thrombocytopenia (32%) with combo. Conclusions: Glofitamab SUD administered as monotherapy or in combination with obinutuzumab achieved high response rates in pts with heavily pretreated R/R FL, including high-risk subgroups. Response rates were comparable to those reported for CAR-T in R/R FL. The safety profile of glofitamab was manageable; CRS events were mostly low grade and occurred mainly in C1 and C2. Considering the short duration of follow-up, additional follow-up is required to further assess the safety and efficacy of glofitamab in this heterogeneously treated population. Further analyses will be presented. Figure 1 Figure 1. Disclosures Morschhauser: BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genentech, Inc.: Consultancy; Genmab: Membership on an entity's Board of Directors or advisory committees; AstraZenenca: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Servier: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Chugai: Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Carlo-Stella: AstraZeneca: Honoraria; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Consultancy, Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Honoraria; Janssen Oncology: Honoraria; Celgene: Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics: Membership on an entity's Board of Directors or advisory committees. Dickinson: Celgene: Research Funding; Takeda: Research Funding; Gilead Sciences: Consultancy, Honoraria, Speakers Bureau; MSD: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Amgen: Honoraria; Roche: Consultancy, Honoraria, Other: travel, accommodation, expenses, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau. Phillips: ADCT, BeiGene, Bristol Myers Squibb, Cardinal Health, Incyte, Karyopharm, Morphosys, Pharmacyclics, Seattle Genetics: Consultancy; AstraZeneca: Consultancy; BMS: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Consultancy, Research Funding; Incyte: Consultancy, Other: received travel expenses from Incyte, Research Funding. Houot: Bristol-Myers Squibb: Honoraria; CHU Rennes: Current Employment; Roche: Honoraria; Kite: Honoraria; Gilead: Honoraria; MSD: Honoraria; Celgene: Honoraria; Jsnssen: Honoraria; Novartis: Honoraria. Haioun: Celgene: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Miltenyi: Honoraria, Research Funding; Servier: Honoraria, Research Funding. Corradini: AbbVie, ADC Theraputics, Amgen, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Honoraria; Incyte: Consultancy; Amgen; Takeda; AbbVie: Consultancy, Honoraria, Other: Travel and accommodations; Novartis; Gilead; Celgene: Consultancy, Other: Travel and accommodations; BMS: Other: Travel and accommodation; Sanofi: Consultancy, Honoraria; KiowaKirin; Incyte; Daiichi Sankyo; Janssen; F. Hoffman-La Roche; Kite; Servier: Consultancy; Novartis, Janssen, Celgene, BMS, Takeda, Gilead/Kite, Amgen, AbbVie: Other: travel and accomodations; AbbVie, ADC Theraputics, Amgen, Celgene, Daiichi Sankyo, Gilead/Kite, GSK, Incyte, Janssen, KyowaKirin, Nerviano Medical Science, Novartis, Roche, Sanofi, Takeda: Consultancy. Hutchings: Novartis: Research Funding; Janssen: Honoraria, Research Funding; Incyte: Research Funding; Genentech: Honoraria, Research Funding; Celgene: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Genmab: Consultancy, Honoraria, Research Funding. Sureda: GSK: Consultancy, Honoraria, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Other: Support for attending meetings and/or travel; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau; Bluebird: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Consultancy. Martínez-López: Janssen, BMS, Novartis, Incyte, Roche, GSK, Pfizer: Consultancy; Roche, Novartis, Incyte, Astellas, BMS: Research Funding. Wrobel: Janssen: Honoraria, Speakers Bureau; Roche: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; BeiGene: Honoraria, Speakers Bureau. Lundberg: F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company. Mulvihill: F. Hoffmann-La Roche Ltd: Current Employment, Ended employment in the past 24 months. Perez-Callejo: F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company. Relf: Harpoon Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; F-Star Therapeutics: Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months; Roche Pharmaceutical Ltd: Current Employment, Current equity holder in publicly-traded company. Panchal: F. Hoffmann-La Roche Ltd: Current Employment. Humphrey: Roche: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Bachy: Kite, a Gilead Company: Honoraria; Novartis: Honoraria; Daiishi: Research Funding; Roche: Consultancy; Takeda: Consultancy; Incyte: Consultancy. OffLabel Disclosure: Glofitamab is a full-length, humanized, immunoglobulin G1 bispecific antibody with a 2:1 molecular format that facilitates bivalent binding to CD20 on B-cells, and monovalent binding to CD3 on T-cells. Glofitamab redirects T cells to engage and eliminate malignant B cells. Glofitamab is an investigational agent. Obinutuzumab (Gazyva) is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of pts with previously untreated CLL; in combination with bendamustine followed by obinutuzumab monotherapy, for the treatment of pts with FL who relapsed after, or are refractory to, a rituximab-containing regimen; in combination with chemo followed by obinutuzumab monotherapy in pts achieving at least a PR, for the treatment of adult pts with previously untreated stage II bulky, III or IV FL

Abstract Background: While remission rates for newly diagnosed AML have improved significantly with modern therapies, relapse remains a major cause of treatment failure and death. Post remission maintenance therapy in AML seeks to delay/prevent relapse with the goal of improving survival. From a historical cohort, among patients who did not receive allogeneic stem cell transplantation (aHSCT) in first remission (CR1), the median relapse-free survival (RFS) was 10m, 8m, and 5.7m for those who had received intensive therapy, lower-intensity therapy, or those with detectable minimal residual disease (MRD), respectively. Oral 5-azacytidine (CC-486) was shown to be effective in prolonging relapse-free and overall survival in AML patients in CR1 following intensive chemotherapy (QUAZAR AML-001). We designed this phase II trial to evaluate the efficacy and feasibility of low-dose IV/SQ 5-azacytidine (AZA) in combination with venetoclax (VEN) as maintenance therapy in AML patients who have achieved CR after high or low-intensity therapy. Methods: Patients ≥ 18 years with AML were eligible for enrollment if they had achieved CR1 (CR/CRi), had ≥ 2 cycles of therapy prior to maintenance, and were not immediately eligible for aHSCT. Patients with detectable MRD in CR1 or beyond were also eligible. Cohort 1 included patients treated with intensive chemotherapy (defined as including standard or higher-dose cytarabine). Cohort 2 consisted of patients treated with low-intensity chemotherapy (defined as including a low-dose cytarabine (LDAC) or hypomethylating agent (HMA) backbone) who had received at least 2 cycles from time of CR/CRi to enrollment. Maintenance consisted of AZA 50 mg/m 2 IV/SQ on days 1-5 and VEN 400 mg PO on days 1-14 every 28 days, for up to 24 cycles. Patients who became eligible for aHSCT were taken off study and censored at the time of transplantation. VEN dosing was adjusted for patients on concomitant CYP3A inhibitors or those with severe cytopenias. The primary outcome was RFS. Secondary outcomes included overall survival (OS), event-free survival (EFS), and toxicity/safety. Flow cytometry-based minimal residual disease (MRD) and a next-generation sequencing (NGS)-based panel of 81 myeloid genes were performed on all patients. Results: 27 patients have been enrolled: 20 in cohort 1, 7 in cohort 2. Patient characteristics are presented in Table 1. 24 patients (89%) were in CR1 and 3 (11%) were in CR2. Prior to initiation of maintenance, patients had received a median of 1 (range 1-3) prior lines of therapy and 18 (67%) had been previously exposed to VEN. Patients have received a median of 3 (range 1-17 cycles) cycles of AZA-VEN maintenance. Starting cycle 1, 16 patients (59%) received 7 days and 11 patients (41%) received 14 days of VEN on protocol. 4 patients (15%) came off study to receive aHSCT. RFS and OS at 6m were 87% and 100% respectively for the full cohort. With a median follow-up of 3.8m (range 0.7-16.5m), the median OS was 16.1m and median RFS has not yet been reached (Figure 1, A-B); median RFS for patients with or without prior VEN was not reached and 10.1m, respectively (p = 0.3). RFS stratified by cohort, ELN risk category, and MRD status at enrollment is shown in Figure 1, C-E. 4 patients (15%) relapsed on maintenance, including 2 high-risk patients with complex karyotype and detectable MRD at enrollment. There were 3 deaths, all among relapsing patients. ELN-favorable patients (n = 11), with a high incidence of normal diploid karyotypes (11/11), NPM1 mutations (11/11) and IDH1/2 mutations (5/11), did particularly well, with no relapses observed so far within this group. Seven patients (26%) were MRD-positive at enrollment. Of these, 1 (14%) converted to MRD-negative on AZA-VEN alone and 3 (43%) converted only after aHSCT. The most common grade 3/4 toxicities were thrombocytopenia (15%), leukopenia (11%), and neutropenic fever (7%). Conclusions: Maintenance therapy with AZA-VEN is a feasible and tolerable strategy in AML patients who have achieved CR following both high- and low-intensity induction regimens. Although longer follow-up is needed, these preliminary results demonstrate encouraging rates of RFS compared to historical expectations. This suggests low doses of AZA and VEN may be effective at controlling disease relapse while minimizing toxicity once CR is achieved. Figure 1 Figure 1. Disclosures Kantarjian: Ascentage: Research Funding; Jazz: Research Funding; NOVA Research: Honoraria; KAHR Medical Ltd: Honoraria; Aptitude Health: Honoraria; AbbVie: Honoraria, Research Funding; BMS: Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Astellas Health: Honoraria; Astra Zeneca: Honoraria; Ipsen Pharmaceuticals: Honoraria; Daiichi-Sankyo: Research Funding; Immunogen: Research Funding; Amgen: Honoraria, Research Funding; Precision Biosciences: Honoraria; Taiho Pharmaceutical Canada: Honoraria. Borthakur: GSK: Consultancy; Takeda: Membership on an entity's Board of Directors or advisory committees; Astex: Research Funding; University of Texas MD Anderson Cancer Center: Current Employment; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Ryvu: Research Funding; ArgenX: Membership on an entity's Board of Directors or advisory committees; Protagonist: Consultancy. Yilmaz: Daiichi-Sankyo: Research Funding; Pfizer: Research Funding. Bose: Constellation Pharmaceuticals: Research Funding; NS Pharma: Research Funding; Pfizer: Research Funding; Sierra Oncology: Honoraria; CTI BioPharma: Honoraria, Research Funding; Novartis: Honoraria; Kartos Therapeutics: Honoraria, Research Funding; Celgene Corporation: Honoraria, Research Funding; Astellas: Research Funding; Promedior: Research Funding; Blueprint Medicines: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. Alvarado: Daiichi-Sankyo: Research Funding; Sun Pharma: Consultancy, Research Funding; FibroGen: Research Funding; BerGenBio: Research Funding; Jazz Pharmaceuticals: Research Funding; CytomX Therapeutics: Consultancy; MEI Pharma: Research Funding; Astex Pharmaceuticals: Research Funding. Pemmaraju: HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; MustangBio: Consultancy, Other; CareDx, Inc.: Consultancy; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; Cellectis S.A. ADR: Other, Research Funding; Plexxicon: Other, Research Funding; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; LFB Biotechnologies: Consultancy; DAVA Oncology: Consultancy; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; Sager Strong Foundation: Other; Springer Science + Business Media: Other; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Roche Diagnostics: Consultancy; Celgene Corporation: Consultancy; Samus: Other, Research Funding; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; Aptitude Health: Consultancy; Affymetrix: Consultancy, Research Funding; Daiichi Sankyo, Inc.: Other, Research Funding; Incyte: Consultancy; Protagonist Therapeutics, Inc.: Consultancy; Clearview Healthcare Partners: Consultancy; Blueprint Medicines: Consultancy; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Takahashi: GSK: Consultancy; Novartis: Consultancy; Symbio Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy. Short: NGMBio: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Honoraria; AstraZeneca: Consultancy; Astellas: Research Funding; Takeda Oncology: Consultancy, Research Funding; Amgen: Consultancy, Honoraria. Issa: Novartis: Consultancy, Research Funding; Syndax Pharmaceuticals: Research Funding; Kura Oncology: Consultancy, Research Funding. Jain: ADC Therapeutics: Honoraria, Research Funding; Servier: Honoraria, Research Funding; Aprea Therapeutics: Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Cellectis: Honoraria, Research Funding; Janssen: Honoraria; Fate Therapeutics: Research Funding; Pfizer: Research Funding; TG Therapeutics: Honoraria; Pharmacyclics: Research Funding; Adaptive Biotechnologies: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Beigene: Honoraria; AstraZeneca: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Precision Biosciences: Honoraria, Research Funding; Incyte: Research Funding. Ferrajoli: Janssen: Other: Advisory Board ; AstraZeneca: Other: Advisory Board, Research Funding; BeiGene: Other: Advisory Board, Research Funding. Burger: TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; AstraZeneca: Consultancy; Beigene: Research Funding, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Daver: Bristol Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Novartis: Consultancy; Abbvie: Consultancy, Research Funding; Sevier: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Astellas: Consultancy, Research Funding; Trovagene: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; Glycomimetics: Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Hanmi: Research Funding; Amgen: Consultancy, Research Funding; Novimmune: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. DiNardo: Takeda: Honoraria; AbbVie: Consultancy, Research Funding; ImmuneOnc: Honoraria, Research Funding; Forma: Honoraria, Research Funding; Agios/Servier: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Foghorn: Honoraria, Research Funding; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding. Konopleva: Sanofi: Other: grant support, Research Funding; Forty Seven: Other: grant support, Research Funding; Calithera: Other: grant support, Research Funding; Rafael Pharmaceuticals: Other: grant support, Research Funding; Ascentage: Other: grant support, Research Funding; AstraZeneca: Other: grant support, Research Funding; F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support; Agios: Other: grant support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding; Stemline Therapeutics: Research Funding; Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding; Ablynx: Other: grant support, Research Funding; Cellectis: Other: grant support; Genentech: Consultancy, Honoraria, Other: grant support, Research Funding; KisoJi: Research Funding; Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights; Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights. Sasaki: Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees. Ravandi: AstraZeneca: Honoraria; AbbVie: Honoraria, Research Funding; Astex: Honoraria, Research Funding; Taiho: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Prelude: Research Funding; Novartis: Honoraria; Xencor: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding. Kadia: Aglos: Consultancy; Pfizer: Consultancy, Other; Ascentage: Other; Cellonkos: Other; Genfleet: Other; Amgen: Other: Grant/research support; AstraZeneca: Other; BMS: Other: Grant/research support; Sanofi-Aventis: Consultancy; Genentech: Consultancy, Other: Grant/research support; Liberum: Consultancy; Jazz: Consultancy; Novartis: Consultancy; Astellas: Other; Dalichi Sankyo: Consultancy; Cure: Speakers Bureau; AbbVie: Consultancy, Other: Grant/research support; Pulmotech: Other. OffLabel Disclosure: Azacytidine SQ/IV and Venetoclax are not currently approved for maintenance in AML

Abstract Background: Inotuzumab ozogamicin (INO) and blinatumomab are effective in the treatment relapsed/ refractory B-cell acute lymphoblastic leukemia (ALL) and improve overall survival (OS) in this setting. The use of these agents in older adults with newly diagnosed B-cell ALL may allow for use of less chemotherapy and improve remission durations and OS compared to standard therapies. Methods: Patients (pts) ≥60 years of age with newly diagnosed Philadelphia chromosome (Ph)-negative pre-B-cell ALL were eligible. Pts were required to have a performance status of ≤3, total bilirubin ≤1.5 mg/dl, AST/ALT ≤3x ULN and creatinine ≤2 mg/dl. Pts received mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5 g/m 2 x 4 doses) for up to 8 cycles. INO was given at a dose of 1.3-1.8mg/m 2 on day 3 of cycle 1 and 0.8-1.3mg/m 2 on day 3 of cycles 2-4. Rituximab (if CD20+) and prophylactic IT chemotherapy were given for the first 4 cycles. Responding pts received POMP maintenance for up to 3 years. In order to decrease the risk of veno-occlusive disease (VOD), the protocol was amended in 3/2017 (pts 50+) to give INO in fractionated doses each cycle (0.6 mg/m 2 on day 2 and 0.3 mg/m 2 on day 8 of cycle 1; 0.3 mg/m 2 on day 2 and 8 of cycles 2-4) and to administer 4 cycles of blinatumomab following 4 cycles of hyper-CVD plus INO, followed by maintenance with 12 cycles of POMP and 4 cycles of blinatumomab (1 cycle of blinatumomab after every 3 cycles of POMP). The cumulative dose of INO given before and after this most recent amendment was 4.3 mg/m 2 and 2.7 mg/m 2, respectively. Results: 75 pts have been treated. 6 pts were in complete remission (CR) at enrollment and unevaluable for morphological response. Pt characteristics are summarized in Table 1. Median age was 68 years (range, 60-87 years); 30 pts (40%) were ≥70 years. 39% were positive for TP53 mutation, 19% had Ph-like ALL (with 6 of the 8 Ph-like pts being CRLF2+ by flow), and 25% had adverse-risk karyotype. Among 69 pts evaluable for morphologic response, 68 (99%) responded (CR, n=61; CRp, n=6; CRi, n=1). MRD negativity by flow cytometry was achieved in 57/71 pts (80%) after 1 cycle and 71/74 pts (96%) overall. The 30-day and 60-day mortality rates were 0% and 3%, respectively. Among 74 pts who achieved remission, 10 (14%) relapsed, 4 (5%) underwent allogeneic SCT in first remission (1 of whom subsequently relapsed), 32 (43%) remain on treatment or have completed therapy, and 28 (38%) died in remission. Overall, 9 pts (12%) developed MDS/AML; in 7 of these cases the myeloid malignancy was TP53-mutated and in the 2 other cases, both the ALL and subsequent AML shared mutations in myeloid mutations (RUNX1, SRSF2, and TET2). Notably, 6 pts (8%) developed VOD, 1 after subsequent allogeneic SCT. The rate of VOD was 6/75 (8%) with no difference in VOD in pts who did or did not receive blinatumomab. With a median follow-up of 56 months (range, 1-111 months), the 5-year continuous remission and OS rates were 76% and 47%, respectively (Figure 1A). Outcomes were superior for those 60-69 years of age versus those who were ≥70 years (5-year OS rates: 58% and 31%, respectively; P=0.04) and for those without poor-risk cytogenetics (e.g. KMT2A rearranged, low hypodiploidy/near triploidy, complex cytogenetics) versus poor-risk cytogenetics (5-year OS rates: 56% and 25%, respectively; P=0.01). Pts ≥70 years of age were more likely to die in remission (20/29 [69%] vs. 19/45 [42%] in pts 60-69 years of age; P=0.03), which was a major driver of the poor survival in this age group. The 5-year OS for pts age 60-69 years with non-poor risk cytogenetics, age 60-69 with poor risk cytogenetics, age ≥70 with non-poor risk cytogenetics and age ≥70 with poor risk cytogenetics were 68%, 37%, 42% and 0% respectively (Figure 1B). Neither Ph-like ALL nor the presence of a TP53 mutation significantly impacted OS (P=0.26 and P=0.34, respectively). Conclusion: Low-intensity chemotherapy with hyper-CVD plus INO, with or without blinatumomab, in older adults with newly diagnosed Ph-negative ALL resulted in an overall response rate of 98% and a 5-year OS rate of 47%. Even with this relatively reduced-intensity regimen, deaths in remission (usually due to infection) occur, primarily in pts ≥70 years of age. A strategy using the combination INO and blinatumomab, without any chemotherapy, is being explored in this population. Figure 1 Figure 1. Disclosures Short: NGMBio: Consultancy; Astellas: Research Funding; AstraZeneca: Consultancy; Novartis: Honoraria; Jazz Pharmaceuticals: Consultancy; Takeda Oncology: Consultancy, Research Funding; Amgen: Consultancy, Honoraria. Kantarjian: BMS: Research Funding; Aptitude Health: Honoraria; NOVA Research: Honoraria; Astra Zeneca: Honoraria; AbbVie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Immunogen: Research Funding; Ascentage: Research Funding; Pfizer: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Astellas Health: Honoraria; Jazz: Research Funding; Daiichi-Sankyo: Research Funding; Ipsen Pharmaceuticals: Honoraria; KAHR Medical Ltd: Honoraria; Precision Biosciences: Honoraria; Taiho Pharmaceutical Canada: Honoraria. Ravandi: Novartis: Honoraria; AbbVie: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Honoraria, Research Funding; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding; Astex: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Prelude: Research Funding; Amgen: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Taiho: Honoraria, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Honoraria. Jain: Janssen: Honoraria; TG Therapeutics: Honoraria; Beigene: Honoraria; Precision Biosciences: Honoraria, Research Funding; Servier: Honoraria, Research Funding; Incyte: Research Funding; Aprea Therapeutics: Research Funding; Fate Therapeutics: Research Funding; AstraZeneca: Honoraria, Research Funding; ADC Therapeutics: Honoraria, Research Funding; Pfizer: Research Funding; Adaptive Biotechnologies: Honoraria, Research Funding; Genentech: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Cellectis: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Pharmacyclics: Research Funding. Kadia: Genfleet: Other; AstraZeneca: Other; Genentech: Consultancy, Other: Grant/research support; Jazz: Consultancy; AbbVie: Consultancy, Other: Grant/research support; Cure: Speakers Bureau; Aglos: Consultancy; Sanofi-Aventis: Consultancy; Pulmotech: Other; Dalichi Sankyo: Consultancy; BMS: Other: Grant/research support; Cellonkos: Other; Pfizer: Consultancy, Other; Astellas: Other; Ascentage: Other; Novartis: Consultancy; Liberum: Consultancy; Amgen: Other: Grant/research support. Khoury: Kiromic: Research Funding; Stemline Therapeutics: Research Funding; Angle: Research Funding. Wang: Stemline Therapeutics: Honoraria. Alvarado: Astex Pharmaceuticals: Research Funding; MEI Pharma: Research Funding; Daiichi-Sankyo: Research Funding; FibroGen: Research Funding; Jazz Pharmaceuticals: Research Funding; CytomX Therapeutics: Consultancy; BerGenBio: Research Funding; Sun Pharma: Consultancy, Research Funding. Burger: Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Beigene: Research Funding, Speakers Bureau; AstraZeneca: Consultancy; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Daver: Bristol Myers Squibb: Consultancy, Research Funding; Novimmune: Research Funding; Glycomimetics: Research Funding; Hanmi: Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Novartis: Consultancy; Trovagene: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Sevier: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. Borthakur: University of Texas MD Anderson Cancer Center: Current Employment; Astex: Research Funding; GSK: Consultancy; ArgenX: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Protagonist: Consultancy; Ryvu: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees. DiNardo: Bristol Myers Squibb: Honoraria, Research Funding; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria; ImmuneOnc: Honoraria, Research Funding; Forma: Honoraria, Research Funding; AbbVie: Consultancy, Research Funding; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Foghorn: Honoraria, Research Funding; Agios/Servier: Consultancy, Honoraria, Research Funding; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding. Konopleva: AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding; Ablynx: Other: grant support, Research Funding; Agios: Other: grant support, Research Funding; Cellectis: Other: grant support; Calithera: Other: grant support, Research Funding; Rafael Pharmaceuticals: Other: grant support, Research Funding; Sanofi: Other: grant support, Research Funding; Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights; KisoJi: Research Funding; Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding; Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights; Stemline Therapeutics: Research Funding; AstraZeneca: Other: grant support, Research Funding; Forty Seven: Other: grant support, Research Funding; F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support; Ascentage: Other: grant support, Research Funding; Genentech: Consultancy, Honoraria, Other: grant support, Research Funding. Pemmaraju: Daiichi Sankyo, Inc.: Other, Research Funding; Springer Science + Business Media: Other; LFB Biotechnologies: Consultancy; Celgene Corporation: Consultancy; Protagonist Therapeutics, Inc.: Consultancy; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Samus: Other, Research Funding; Plexxicon: Other, Research Funding; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; MustangBio: Consultancy, Other; Incyte: Consultancy; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; DAVA Oncology: Consultancy; HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Cellectis S.A. ADR: Other, Research Funding; Affymetrix: Consultancy, Research Funding; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; Clearview Healthcare Partners: Consultancy; Roche Diagnostics: Consultancy; Sager Strong Foundation: Other; Aptitude Health: Consultancy; CareDx, Inc.: Consultancy; Blueprint Medicines: Consultancy; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Wierda: Miragen: Research Funding; GSK/Novartis: Research Funding; Loxo Oncology, Inc.: Research Funding; Acerta Pharma Inc.: Research Funding; Karyopharm: Research Funding; Janssen: Research Funding; Juno Therapeutics: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Gilead Sciences: Research Funding; Genentech: Research Funding; AstraZeneca: Research Funding; Xencor: Research Funding; Cyclacel: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Sunesis: Research Funding; KITE Pharma: Research Funding; Genzyme Corporation: Consultancy; AbbVie: Research Funding. O'Brien: Kite, Regeneron, Acerta, Caribou, Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis: Research Funding; Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, AbbVie, Alexion, Verastem, Juno Therapeutics, Vida Ventures, Autolus, Johnson and Johnson, Merck, Bristol Myers Squibb, NOVA Research Company, Eli Lill: Consultancy. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. OffLabel Disclosure: Blinatumomab and inotuzumab as frontline therapy for B-cell ALL

Abstract Background: DEC10-VEN is an effective regimen and offers better outcomes compared to intensive chemotherapy in older pts with newly diagnosed (ND) or relapsed/refractory (R/R) AML (Maiti. Am J Hematol 2021; Maiti. Cancer 2021). We report long term outcomes in major genomic subgroups. Methods: Pts received decitabine 20 mg/m 2 on D1-10 until CR/CRi, followed by 5-day cycles. VEN dose was 400 mg daily but held on C1D21 if D21 bone marrow (BM) had ≤5% blasts. VEN could be reduced to <14 days in cases of myelosuppression (DiNardo. Lancet Haematol 2020). Treatment-naïve group included pts with ND and secondary AML (sAML) without therapy for antecedent hematological disorder (AHD). Previously treated AML included sAML with prior therapy for AHD and R/R AML. Concomitant TKIs included gilteritinib (18), sorafenib (13), midostaurin (5), enasidenib (3) and ponatinib (1). Eligible pts could proceed to stem cell transplantation (SCT) after response. Endpoints were defined per ELN2017. NGS targeting entire coding regions of 81 myeloid genes was performed on screening BM sample with an analytical sensitivity of 5%. Measurable residual disease (MRD) was tested by multiparametric flow cytometry (sensitivity 0.1%). Results: Between January 2018 and April 2021 we enrolled 199 pts with ND AML (n=83), untreated sAML (n=20), treated sAML (n=25), and R/R AML (n=71). Median age of treatment-naïve pts was 72 yrs (range 61-72) and of previously treated pts was 67 yrs (range 18-85, Table 1). No pts had favorable risk cytogenetics. Median no. of prior therapies in previously treated pts was 2 (range 1-8) and 24% pts (23/96) had prior SCT. 21 treatment-naïve and 20 previously treated pts underwent SCT after response. Median follow-up for all pts was 25.4 mo. Among treatment-naïve pts, CR/CRi rates were high in all mutations subgroups ranging from 70-88% in pts with NPM1mut, FLT3mut, IDH1/2mut, TP53mut, RUNX1mut, K/NRASmut. Pts with ASXL1mut had modest CR/CRi rate of 56% (Table 2). FLT3 TKI was used in 71% FLT3mut pts (n=15/21). MRD negative rate among responding pts were high across all mutational subgroups ranging from 62-91%, except 55% in pts with ASXL1mut and 50% in pts with TP53mut. Median overall survival (OS) for treatment-naïve pts with NPM1mut was not reached (NR), IDH1/2mut was 29.6 mo, FLT3mut was 24.5 mo, RUNX1mut was 16.2 mo, ASXL1mut was 15.2 mo, K/NRASmut was 12.1 mo and TP53mut was 5.4 mo (Fig 1a-b). The median relapse-free survival (RFS) among treatment-naïve pts with NPM1mut was NR, IDH1/2mut was NR, FLT3mut was 20.0 mo, RUNX1mut was 9.7 mo, ASXL1mut was 8.5 mo, K/NRASmut was 6.5 mo and TP53mut was 3.1 mo (Fig 1c-d). Among NPM1+FLT3 co-mutated pts, outcomes in treatment-naïve pts (n=26) included ORR of 96%, CR/CRi in 88%, MRD negative in 92% (22/24), median OS NR and median RFS NR. Among previously treated NPM1+FLT3 pts (n=9), ORR was 78%, CR/CRi in 56%, MRD negative in 86% (6/7), median OS 12.4 mo and median RFS 6.6 mo. Among NPM1+DNMT3A co-mutated pts, outcomes in treatment-naïve pts (n=28) included ORR of 93%, CR/CRi in 89%, MRD negative in 79% (19/24), median OS 15.2 mo and median RFS 9.0 mo. Among previously treated NPM1+DNMT3A pts (n=6), ORR was 75%, CR/CRi in 50%, MRD negative in 75% (3/4), median OS was 4.7 mo and median RFS was 5.2 mo. Among previously treated pts CR/CRi rates in pts with NPM1mut was 68%, IDH1/2mut 50%, FLT3mut 42%, RUNX1mut 45%, ASXL1mut 38%, TP53mut 30%, and K/NRASmut was 26% (Table 2). FLT3 TKI used in 95% of FLT3mut pts (n=18/19). MRD negative rate among responding pts were high for pts with NPM1mut, FLT3mut, IDH1/2mut, RUNX1mut and ASXL1mut ranging from 60-87%, but were low for pts with K/NRASmut at 56% and TP53mut at 37%. The median OS among previously treated pts with IDH1/2mut was 16.9 mo, RUNX1mut was 13.7 mo, NPM1mut was 12.4 mo, ASXL1mut was 9.0 mo, FLT3mut was 6.4 mo, K/NRASmut was 6.0 mo, and for TP53mut was 4.5 mo (Fig 1e-f). The median RFS among treatment-naïve pts with K/NRASmut was 18.9 mo, NPM1mut was 15.6 mo, IDH1/2mut was 15.3, RUNX1mut was 12.9 mo, ASXL1mut was 10.7 mo, TP53mut was 9.4 mo, and for FLT3mut was 6.6 mo (Fig 1g-h). Conclusions: DEC10-VEN offered high rates of CR/CRi, negative MRD, favorable OS and RFS across several genomic subgroups of treatment-naïve AML including NPM1, FLT3, IDH1/2 and modest outcomes in pts with these mutations in salvage setting. Outcomes in pts with TP53, RUNX1, ASXL1 and K/NRAS were suboptimal. Outcomes with FLT3 VEN HMA triplet was encouraging, particularly for frontline FLT3mut pts. Figure 1 Figure 1. Disclosures DiNardo: Novartis: Honoraria; Takeda: Honoraria; ImmuneOnc: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Agios/Servier: Consultancy, Honoraria, Research Funding; Foghorn: Honoraria, Research Funding; AbbVie: Consultancy, Research Funding; Forma: Honoraria, Research Funding; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding. Pemmaraju: Affymetrix: Consultancy, Research Funding; Cellectis S.A. ADR: Other, Research Funding; Samus: Other, Research Funding; Blueprint Medicines: Consultancy; Celgene Corporation: Consultancy; Clearview Healthcare Partners: Consultancy; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; Protagonist Therapeutics, Inc.: Consultancy; Aptitude Health: Consultancy; Incyte: Consultancy; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; LFB Biotechnologies: Consultancy; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; Sager Strong Foundation: Other; Plexxicon: Other, Research Funding; CareDx, Inc.: Consultancy; Daiichi Sankyo, Inc.: Other, Research Funding; Springer Science + Business Media: Other; DAVA Oncology: Consultancy; Roche Diagnostics: Consultancy; MustangBio: Consultancy, Other; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Daver: Amgen: Consultancy, Research Funding; Trovagene: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Sevier: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Hanmi: Research Funding; Genentech: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novimmune: Research Funding; Glycomimetics: Research Funding; Trillium: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Novartis: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. Issa: Syndax Pharmaceuticals: Research Funding; Novartis: Consultancy, Research Funding; Kura Oncology: Consultancy, Research Funding. Borthakur: Astex: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; University of Texas MD Anderson Cancer Center: Current Employment; Ryvu: Research Funding; Protagonist: Consultancy; Takeda: Membership on an entity's Board of Directors or advisory committees; ArgenX: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy. Ravandi: Taiho: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Agios: Honoraria, Research Funding; Xencor: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astex: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Prelude: Research Funding; AbbVie: Honoraria, Research Funding; AstraZeneca: Honoraria; Novartis: Honoraria; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding. Alvarado: BerGenBio: Research Funding; Jazz Pharmaceuticals: Research Funding; Sun Pharma: Consultancy, Research Funding; MEI Pharma: Research Funding; FibroGen: Research Funding; CytomX Therapeutics: Consultancy; Daiichi-Sankyo: Research Funding; Astex Pharmaceuticals: Research Funding. Kadia: BMS: Other: Grant/research support; Dalichi Sankyo: Consultancy; Cure: Speakers Bureau; Jazz: Consultancy; Liberum: Consultancy; Aglos: Consultancy; Amgen: Other: Grant/research support; Novartis: Consultancy; AbbVie: Consultancy, Other: Grant/research support; Genentech: Consultancy, Other: Grant/research support; Pfizer: Consultancy, Other; Pulmotech: Other; Sanofi-Aventis: Consultancy; Cellonkos: Other; Ascentage: Other; Genfleet: Other; Astellas: Other; AstraZeneca: Other. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. Short: Novartis: Honoraria; Jazz Pharmaceuticals: Consultancy; NGMBio: Consultancy; Astellas: Research Funding; AstraZeneca: Consultancy; Takeda Oncology: Consultancy, Research Funding; Amgen: Consultancy, Honoraria. Jain: Adaptive Biotechnologies: Honoraria, Research Funding; Janssen: Honoraria; Aprea Therapeutics: Research Funding; Genentech: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; Precision Biosciences: Honoraria, Research Funding; Fate Therapeutics: Research Funding; Servier: Honoraria, Research Funding; ADC Therapeutics: Honoraria, Research Funding; TG Therapeutics: Honoraria; Beigene: Honoraria; Incyte: Research Funding; Cellectis: Honoraria, Research Funding; Pfizer: Research Funding; AstraZeneca: Honoraria, Research Funding; Pharmacyclics: Research Funding; AbbVie: Honoraria, Research Funding. Wierda: Juno Therapeutics: Research Funding; KITE Pharma: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Cyclacel: Research Funding; Loxo Oncology, Inc.: Research Funding; Acerta Pharma Inc.: Research Funding; Genzyme Corporation: Consultancy; Miragen: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Sunesis: Research Funding; GSK/Novartis: Research Funding; Genentech: Research Funding; Gilead Sciences: Research Funding; Xencor: Research Funding; Janssen: Research Funding; Karyopharm: Research Funding; AbbVie: Research Funding; AstraZeneca: Research Funding. Sasaki: Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees. Takahashi: GSK: Consultancy; Celgene/BMS: Consultancy; Symbio Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy. Yilmaz: Daiichi-Sankyo: Research Funding; Pfizer: Research Funding. Burger: Beigene: Research Funding, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; AstraZeneca: Consultancy; Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Verstovsek: Incyte Corporation: Consultancy, Research Funding; PharmaEssentia: Research Funding; Promedior: Research Funding; AstraZeneca: Research Funding; NS Pharma: Research Funding; Ital Pharma: Research Funding; Celgene: Consultancy, Research Funding; Protagonist Therapeutics: Research Funding; Roche: Research Funding; Sierra Oncology: Consultancy, Research Funding; Gilead: Research Funding; Genentech: Research Funding; CTI BioPharma: Research Funding; Blueprint Medicines Corp: Research Funding; Novartis: Consultancy, Research Funding; Constellation: Consultancy; Pragmatist: Consultancy. Andreeff: Karyopharm: Research Funding; Syndax: Consultancy; Medicxi: Consultancy; Oxford Biomedica UK: Research Funding; Amgen: Research Funding; ONO Pharmaceuticals: Research Funding; Glycomimetics: Consultancy; Novartis, Cancer UK; Leukemia & Lymphoma Society (LLS), German Research Council; NCI-RDCRN (Rare Disease Clin Network), CLL Foundation; Novartis: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Research Funding; Breast Cancer Research Foundation: Research Funding; Aptose: Consultancy; Senti-Bio: Consultancy; AstraZeneca: Research Funding; Reata, Aptose, Eutropics, SentiBio; Chimerix, Oncolyze: Current holder of individual stocks in a privately-held company. Bose: CTI BioPharma: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; Astellas: Research Funding; Kartos Therapeutics: Honoraria, Research Funding; Sierra Oncology: Honoraria; NS Pharma: Research Funding; Celgene Corporation: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Blueprint Medicines: Honoraria, Research Funding; Novartis: Honoraria; Constellation Pharmaceuticals: Research Funding; Pfizer: Research Funding; Promedior: Research Funding. Ferrajoli: BeiGene: Other: Advisory Board, Research Funding; Janssen: Other: Advisory Board ; AstraZeneca: Other: Advisory Board, Research Funding. Thompson: Gilead: Other: Institution: Advisory/Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Pharmacyclics: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Adaptive Biotechnologies: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding, Expert Testimony; Genentech: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Amgen: Other: Institution: Honoraria, Research Grant/Funding. Welch: Janssen: Research Funding; Notable Labs: Research Funding. Kantarjian: Ipsen Pharmaceuticals: Honoraria; Immunogen: Research Funding; Pfizer: Honoraria, Research Funding; Aptitude Health: Honoraria; Jazz: Research Funding; NOVA Research: Honoraria; KAHR Medical Ltd: Honoraria; Astellas Health: Honoraria; Daiichi-Sankyo: Research Funding; BMS: Research Funding; AbbVie: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Astra Zeneca: Honoraria; Amgen: Honoraria, Research Funding; Ascentage: Research Funding; Precision Biosciences: Honoraria; Taiho Pharmaceutical Canada: Honoraria. Konopleva: Ablynx: Other: grant support, Research Funding; Agios: Other: grant support, Research Funding; Rafael Pharmaceuticals: Other: grant support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding; AstraZeneca: Other: grant support, Research Funding; Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights; Ascentage: Other: grant support, Research Funding; Calithera: Other: grant support, Research Funding; Forty Seven: Other: grant support, Research Funding; F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support; Cellectis: Other: grant support; KisoJi: Research Funding; Genentech: Consultancy, Honoraria, Other: grant support, Research Funding; Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights; Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding; Sanofi: Other: grant support, Research Funding; Stemline Therapeutics: Research Funding. OffLabel Disclosure: Off-label use - venetoclax in relapsed/refractory AML

Abstract Background: Older patients (pt) with acute myeloid leukemia (AML) and patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia (HR MDS/CMML) have poor outcomes. We showed that 10-day decitabine with venetoclax (DEC10-VEN) is a safe and effective strategy and offers potentially better outcomes compared to intensive chemotherapy in older pts with newly diagnosed (ND) AML, as well as relapsed or refractory (R/R) AML (DiNardo et al. Lancet Haematol 2020; Maiti et al. Am J Hematol 2021; Maiti et al. Cancer 2021). We here in present updated results of this prospective phase II trial (NCT03404193). Methods: Eligibility criteria included ECOG PS ≤3, WBC ≤10 x10 9/L, and adequate organ function. Decitabine dose was 20 mg/m 2 IV daily on D1-10 until CR/CRi, followed by 5-day cycles. Venetoclax was given on D1-28 in cycle 1 but was interrupted on C1D21 until count recovery if the D21 bone marrow (BM) had ≤5% blasts. Venetoclax dose was 400 mg PO daily or equivalent with concomitant azole antifungals as previously described (DiNardo et al. Lancet Haematol. 2020). Venetoclax duration could be reduced to 14 to 7 days in subsequent cycles in cases of prolonged myelosuppression. All pts received cytoreduction prior to start, tumor lysis syndrome (TLS) prophylaxis and antimicrobial prophylaxis. Concomitant FLT3 tyrosine kinase inhibitors were allowed in FLT3-mutated AML. Pts could proceed to allogeneic stem-cell transplantation (SCT) after response, if eligible. Primary objective was overall response rate and secondary objectives included safety and overall survival. Outcomes and endpoints were defined per ELN2017 criteria. Measurable residual disease (MRD) was assessed using multiparametric flow cytometry (sensitivity 0.1%) and reported for all responding pts with evaluable MRD sample. Results: Between January 2018 and April 2021 we enrolled 219 pts with ND AML (n=83), untreated sAML (n=20), treated sAML (n=25), R/R AML (n=71) and HR MDS/CMML (n=20). This high-risk cohort included 54% of pts ≥70 yrs (n=119), 57% pts were men, 29% pts had ECOG PS ≥2, and 57% pts had adverse-risk AML (Table 1). The 30 mortality was 1% for ND pts and 3.6% for all pts. There were 346 treatment-related adverse events in 181 patients including infections with grade 3/4 neutropenia (40%), febrile neutropenia (29%), and infection with unknown ANC (17%, Table 2). There were 11 grade 5 events including infections with grade 3/4 neutropenia (n=6), infections with unknown ANC (n=4), and renal failure (n=1). The CR/CRi rate in ND AML was 83%, in untreated sAML was 65%, in treated sAML was 40%, in R/R AML was 42% and in HR-MDS/CMML was 20% (Table 3). Rates of negative measurable residual disease (MRD) by flow cytometry (0.1%) in ND AML was 73%, in untreated sAML was 53%, in treated sAML was 65%, and in R/R AM was 58%. After a median follow-up of 24.7 months (mo), the median OS in ND AML was 16.2 mo, in untreated sAML was 10.7 mo, in treated sAML was 5.8 mo, in R/R AML was 7.8 mo, and in HR-MDS/CMML was 10.1 mo (Fig. 1a). The 1-yr OS in ND AML was 54%, in untreated sAML was 41%, in treated sAML was 36%, in R/R AML was 41%, and in HR MDS/CMML was 35%. Median RFS for pts with ND AML was 10.9 mo, in the untreated sAML was 6.7 mo, in treated sAML was 11.4 mo, and in R/R AML was 8.4 mo (Fig. 1b). 44 pts underwent SCT after achieving response including ND AML (n=17), untreated sAML (n=4), treated sAML (n=3), R/R AML (n=16), and HR-MDS/CMML (n=4). The 100-day post-SCT mortality was 9% (n=4). Median OS after SCT in pts with previously untreated AML was 31.1 mo and in previously treated AML was 15.0 mo (Fig. 1c) 199 pts (91%) have discontinued treatment and 69 pts (32%) are alive. The most common reasons for treatment discontinuation included refractory disease in 49 pts (22%), relapse in 45 pts (21%), SCT in 44 pts (20%). Conclusions: DEC10-VEN is an effective therapy for older pts with ND and R/R AML. Transition to SCT after response with DEC10-VEN may offer long-term survival advantage in this older/unfit population with both ND and R/R AML. The trial continues to accrue. Based on these findings we have initiated a phase II trial of 10-day oral decitabine (ASTX727) with venetoclax in R/R AML (NCT04975919). Figure 1 Figure 1. Disclosures DiNardo: GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Notable Labs: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; ImmuneOnc: Honoraria, Research Funding; Forma: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; AbbVie: Consultancy, Research Funding; Agios/Servier: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Novartis: Honoraria; Foghorn: Honoraria, Research Funding; Celgene, a Bristol Myers Squibb company: Honoraria, Research Funding. Pemmaraju: DAVA Oncology: Consultancy; ASCO Leukemia Advisory Panel: Membership on an entity's Board of Directors or advisory committees; Dan's House of Hope: Membership on an entity's Board of Directors or advisory committees; HemOnc Times/Oncology Times: Membership on an entity's Board of Directors or advisory committees; Sager Strong Foundation: Other; Cellectis S.A. ADR: Other, Research Funding; CareDx, Inc.: Consultancy; Springer Science + Business Media: Other; MustangBio: Consultancy, Other; Stemline Therapeutics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; LFB Biotechnologies: Consultancy; Daiichi Sankyo, Inc.: Other, Research Funding; Affymetrix: Consultancy, Research Funding; Roche Diagnostics: Consultancy; Samus: Other, Research Funding; Blueprint Medicines: Consultancy; Clearview Healthcare Partners: Consultancy; Novartis Pharmaceuticals: Consultancy, Other: Research Support, Research Funding; Celgene Corporation: Consultancy; Incyte: Consultancy; Protagonist Therapeutics, Inc.: Consultancy; Abbvie Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; Plexxicon: Other, Research Funding; Aptitude Health: Consultancy; ASH Communications Committee: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb Co.: Consultancy; ImmunoGen, Inc: Consultancy; Pacylex Pharmaceuticals: Consultancy. Daver: Novartis: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: Data Monitoring Committee member; Trovagene: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; FATE Therapeutics: Research Funding; Hanmi: Research Funding; Amgen: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Novimmune: Research Funding; Astellas: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Sevier: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Glycomimetics: Research Funding; Gilead Sciences, Inc.: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; Dava Oncology (Arog): Consultancy; Celgene: Consultancy; Syndax: Consultancy; Shattuck Labs: Consultancy; Agios: Consultancy; Kite Pharmaceuticals: Consultancy; SOBI: Consultancy; STAR Therapeutics: Consultancy; Karyopharm: Research Funding; Newave: Research Funding. Issa: Kura Oncology: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Syndax Pharmaceuticals: Research Funding. Borthakur: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy; ArgenX: Membership on an entity's Board of Directors or advisory committees; Ryvu: Research Funding; University of Texas MD Anderson Cancer Center: Current Employment; Astex: Research Funding; Protagonist: Consultancy. Ravandi: Astex: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Taiho: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Xencor: Honoraria, Research Funding; Agios: Honoraria, Research Funding; AstraZeneca: Honoraria; Prelude: Research Funding; Novartis: Honoraria; AbbVie: Honoraria, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz: Honoraria, Research Funding; Syros Pharmaceuticals: Consultancy, Honoraria, Research Funding. Alvarado: MEI Pharma: Research Funding; Astex Pharmaceuticals: Research Funding; FibroGen: Research Funding; Jazz Pharmaceuticals: Research Funding; Daiichi-Sankyo: Research Funding; BerGenBio: Research Funding; CytomX Therapeutics: Consultancy; Sun Pharma: Consultancy, Research Funding. Kadia: AbbVie: Consultancy, Other: Grant/research support; Cure: Speakers Bureau; Genfleet: Other; Cellonkos: Other; Sanofi-Aventis: Consultancy; Liberum: Consultancy; Astellas: Other; AstraZeneca: Other; Jazz: Consultancy; Genentech: Consultancy, Other: Grant/research support; BMS: Other: Grant/research support; Dalichi Sankyo: Consultancy; Ascentage: Other; Pulmotech: Other; Novartis: Consultancy; Pfizer: Consultancy, Other; Aglos: Consultancy; Amgen: Other: Grant/research support. Short: Takeda Oncology: Consultancy, Research Funding; Amgen: Consultancy, Honoraria; Astellas: Research Funding; AstraZeneca: Consultancy; Jazz Pharmaceuticals: Consultancy; NGMBio: Consultancy; Novartis: Honoraria. Jabbour: Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, Genentech: Research Funding. Jain: Bristol Myers Squibb: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; Pfizer: Research Funding; Servier: Honoraria, Research Funding; Janssen: Honoraria; Incyte: Research Funding; Adaptive Biotechnologies: Honoraria, Research Funding; Precision Biosciences: Honoraria, Research Funding; Aprea Therapeutics: Research Funding; Fate Therapeutics: Research Funding; Beigene: Honoraria; Cellectis: Honoraria, Research Funding; ADC Therapeutics: Honoraria, Research Funding; TG Therapeutics: Honoraria; Genentech: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Pharmacyclics: Research Funding. Wierda: Janssen: Research Funding; Karyopharm: Research Funding; Genentech: Research Funding; Xencor: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; Acerta Pharma Inc.: Research Funding; AstraZeneca: Research Funding; Juno Therapeutics: Research Funding; Gilead Sciences: Research Funding; Cyclacel: Research Funding; Oncternal Therapeutics, Inc.: Research Funding; Miragen: Research Funding; Sunesis: Research Funding; GSK/Novartis: Research Funding; KITE Pharma: Research Funding; Loxo Oncology, Inc.: Research Funding; Genzyme Corporation: Consultancy; AbbVie: Research Funding. Sasaki: Novartis: Consultancy, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Membership on an entity's Board of Directors or advisory committees. Takahashi: Novartis: Consultancy; Celgene/BMS: Consultancy; GSK: Consultancy; Symbio Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees. Yilmaz: Daiichi-Sankyo: Research Funding; Pfizer: Research Funding. Burger: AstraZeneca: Consultancy; Gilead: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Pharmacyclics LLC: Consultancy, Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; TG Therapeutics: Other: Travel/Accommodations/Expenses, Research Funding, Speakers Bureau; Novartis: Other: Travel/Accommodations/Expenses, Speakers Bureau; Beigene: Research Funding, Speakers Bureau; Janssen: Consultancy, Other: Travel/Accommodations/Expenses, Speakers Bureau. Verstovsek: CTI BioPharma: Research Funding; Ital Pharma: Research Funding; Incyte Corporation: Consultancy, Research Funding; Gilead: Research Funding; Genentech: Research Funding; PharmaEssentia: Research Funding; Promedior: Research Funding; Protagonist Therapeutics: Research Funding; Roche: Research Funding; NS Pharma: Research Funding; Blueprint Medicines Corp: Research Funding; Celgene: Consultancy, Research Funding; Sierra Oncology: Consultancy, Research Funding; AstraZeneca: Research Funding; Novartis: Consultancy, Research Funding; Constellation: Consultancy; Pragmatist: Consultancy. Andreeff: Glycomimetics: Consultancy; Aptose: Consultancy; AstraZeneca: Research Funding; Oxford Biomedica UK: Research Funding; Amgen: Research Funding; Syndax: Consultancy; Medicxi: Consultancy; Novartis, Cancer UK; Leukemia & Lymphoma Society (LLS), German Research Council; NCI-RDCRN (Rare Disease Clin Network), CLL Foundation; Novartis: Membership on an entity's Board of Directors or advisory committees; Breast Cancer Research Foundation: Research Funding; Reata, Aptose, Eutropics, SentiBio; Chimerix, Oncolyze: Current holder of individual stocks in a privately-held company; ONO Pharmaceuticals: Research Funding; Karyopharm: Research Funding; Daiichi-Sankyo: Consultancy, Research Funding; Senti-Bio: Consultancy. Bose: Pfizer: Research Funding; Constellation Pharmaceuticals: Research Funding; Novartis: Honoraria; Sierra Oncology: Honoraria; Kartos Therapeutics: Honoraria, Research Funding; Blueprint Medicines: Honoraria, Research Funding; CTI BioPharma: Honoraria, Research Funding; Celgene Corporation: Honoraria, Research Funding; BMS: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; Astellas: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding. Ferrajoli: AstraZeneca: Other: Advisory Board, Research Funding; BeiGene: Other: Advisory Board, Research Funding; Janssen: Other: Advisory Board . Thompson: Adaptive Biotechnologies: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding, Expert Testimony; Pharmacyclics: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Janssen: Consultancy, Honoraria; Gilead: Other: Institution: Advisory/Consultancy, Honoraria; AbbVie: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Genentech: Other: Institution: Advisory/Consultancy, Honoraria, Research Grant/Funding; Amgen: Other: Institution: Honoraria, Research Grant/Funding. Kantarjian: AbbVie: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Immunogen: Research Funding; BMS: Research Funding; Jazz: Research Funding; Ascentage: Research Funding; Daiichi-Sankyo: Research Funding; Ipsen Pharmaceuticals: Honoraria; Astra Zeneca: Honoraria; KAHR Medical Ltd: Honoraria; Aptitude Health: Honoraria; Pfizer: Honoraria, Research Funding; Astellas Health: Honoraria; Novartis: Honoraria, Research Funding; NOVA Research: Honoraria; Precision Biosciences: Honoraria; Taiho Pharmaceutical Canada: Honoraria. Konopleva: Agios: Other: grant support, Research Funding; Calithera: Other: grant support, Research Funding; Rafael Pharmaceuticals: Other: grant support, Research Funding; KisoJi: Research Funding; Eli Lilly: Patents & Royalties: intellectual property rights, Research Funding; Reata Pharmaceuticals: Current holder of stock options in a privately-held company, Patents & Royalties: intellectual property rights; Novartis: Other: research funding pending, Patents & Royalties: intellectual property rights; Cellectis: Other: grant support; Ascentage: Other: grant support, Research Funding; AstraZeneca: Other: grant support, Research Funding; Sanofi: Other: grant support, Research Funding; Ablynx: Other: grant support, Research Funding; Genentech: Consultancy, Honoraria, Other: grant support, Research Funding; Forty Seven: Other: grant support, Research Funding; AbbVie: Consultancy, Honoraria, Other: Grant Support, Research Funding; Stemline Therapeutics: Research Funding; F. Hoffmann-La Roche: Consultancy, Honoraria, Other: grant support.

ContextThe COVID-19 pandemic has placed a tremendous stress on healthcare systems and caused reorganization. As the pandemic intensifies, identifying the profile of patients with COVID-19 was primordial in order to predict negative outcomes and organize healthcare resources. Age is associated with COVID-19’s mortality, but for obvious ethical reasons, chronological age cannot be the sole criterion for predicting negative outcomes.ObjectiveThe objective of this study was to determine the relationship between frailty index (FI) and length of hospital stay, and death in a non-COVID population of patients aged 75 years old and above.Methods and designA retrospective, analytical, single-centered observational study was performed in the geriatric short-stay accommodation unit at Guadeloupe University Hospital. For this study, 158 patients who were at least 75 years old were recruited from November 2020 to May 2021. FI was calculated as the number of deficits in a participant divided by the total number of deficits considered (the cut-off of FI is.25 in outpatient). Multivariate logistics regression analyses were conducted to assess the association between frailty and death, and length of stay.ResultsThe average age of the participants was 85.7 ± 6.74 with a range of 75–104. Twenty-four of the patients died during hospitalization. FI was only significantly associated with mortality even after adjustment for age and gender (HR 26.3, 95% CI 1.7–413.4, P = 0.021). The association was stronger in the highest tertile of the FI (age- and gender-adjusted HR 4.6, 95% CI 1.39–15.11, P = 0.01). There was no significant interaction between FI and length of stay.ConclusionOur study shows an association between FI (in terms of age-related deficit accumulation) and mortality in a non-COVID geriatric short-stay unit in Guadeloupe. The FI seems to have a lower capacity to catch events such as length of stay in this very complex population. Further research studies have to be conducted for better understanding and investigation of our findings.

Abstract Background The NHS Mental Health Implementation Plan aims to reduce length of inpatient psychiatric stays to a maximum of 32 days, yet provides little guidance on how to achieve this. Previous studies have attempted to analyse factors influencing length of stay in mental health units, focussing mostly on patient factors. These models fail to sufficiently explain the variation in duration of inpatient stay. We assess how the type of service delivered by a trust, in addition to patient factors, influences length of stay. Methods We conducted a retrospective case cohort study in a large inner-city NHS mental health trust for all admissions in a 1 month period. Data was gathered from electronic notes of 105 patients. Descriptive univariate and bivariate analyses were conducted on the data, with multiple regression analysis conducted on statistically significant data. Results Short-stay assessment ward admission significantly reduced length of stay. Patients under outpatients or under care co-ordination, admitted through Mental Health Act assessment and formally detained all had longer length of stay. Out of area admissions, locum Consultant care, changing Responsible Clinician and ward transfers all led to longer length of stay. Factors indicating more severe illness such as increased observation level and polypharmacy, as well as diagnoses of psychosis or bipolar disorder were associated with longer duration of stay. Discharges requiring referral to accommodation or rehabilitation led to longer stays. The most significant factors that influenced length of stay were higher observation levels, diagnosis of psychotic illness or bipolar, and discharge to rehabilitation placement. The final model, taking into account all these factors, was able to account for 59.6% of the variability in length of stay. Conclusions The study backs up existing literature which shows patient-factors have an influence on length of stay. The study also demonstrates that service-level factors have an impact on the duration of stay. This data may be used to inform further studies which may aid provision of inpatient and community services in the future.

Purpose This paper explores how Airbnb hosts' experiences with and responses to the coronavirus disease 2019 (COVID-19) health crisis may differ according to their motivations to host and to the type and spatial layout of their Airbnb accommodation. Based on these insights, the paper reflects on the lessons that are learned for the future of short-term rentals. Design/methodology/approach This is a qualitative multi-method small-scale case study, which relies on in-depth interviews and a focus group discussion carried out with a group of hosts affiliated to the Airbnb Host Community in Aarhus, Denmark. Informed by an interpretivist approach, the study aims to make sense of people's subjective experiences with hosting on the Airbnb platform, and how they have continued and adapted their hospitality practices during the pandemic. Findings Participants' adaptive practices vary according to their motivations to host and the type of accommodation that they rent out. Although all hosts in this study now implement more intensive cleaning practices, hosts who stay with their guests onsite tend to take stricter preventative measures to avoid contamination and transmission of the virus in their social interactions with guests. On the contrary, hosts who rent out their entire properties and have minimal contact with their guests found themselves less affected by the pandemic's impacts and have had a continued demand for their properties. Social implications The COVID-19 pandemic has unevenly affected Airbnb hosts. Hosts who share their homes with guests require different adaptations to their daily behaviour and cleaning practices at home than hosts who do not stay with their guests and rent out entire properties. However, unlike professional hosts who largely or solely rely on Airbnb for their income, occasional home-sharing hosts tend to be more flexible in coping with cancelled or fewer bookings. Originality/value This study provides novel insights into the uneven impact of the COVID-19 pandemic on participants in the platform economies of tourism. It contributes to existing literature on the impacts of the pandemic on Airbnb's operations by showing how hosts' adaptive practices are informed by their subjective living conditions and the type of accommodation they can offer their guests.

Purpose This viewpoint paper aims to provide reflections on the role of second homes in the tourism and housing markets together with future lines of research during and after the first outbreak of the COVID-19 (coronavirus disease 2019) pandemic. The authors aim to review the epistemological evolution of the term “second homes” because of the pandemic, as well as to unfold possible short-, medium- and long-term effects that could place second homes at the center of tourist activity and of the tourist rental market profitability. Design/methodology/approach This paper is based on published research studies about the definition of the term “second homes”, as well as media sources related to their role during the current situation of the first outbreak of the COVID-19 pandemic. Findings In the early stages of the pandemic, second-home owners migrated from crowded cities to low-density areas, being vectors of transmission of the virus. Now, a potential shift in tourist preferences could position second homes at the center of tourist activity as soon as travel restrictions are reduced. This could intensify existing processes of commodification of housing, empowering accommodation platforms and situating the potential for profiteering around the tourist rental market. Parallely, international interests in migrating from crowded cities to low-density areas could also be triggered. Originality/value This viewpoint is presented as the confinement measures associated with the new pandemic are being de-escalated in most of the western countries. It is expected that sharing it will provide insights to researchers and practitioners to better plan their research around secondary housing. Its role should be analysed from different perspectives: in the spread of the virus to low-density areas to anticipate mitigation actions in future outbreaks; in the recovery process of (domestic) tourism; in the processes of commodification and financialization of housing in tourist areas; and their impacts on local residents.